QUARTERLY REPORT

Q2 2024 — Quarterly report

Q2 2024PDF · 51 pages548 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2024
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey 22-1918501
(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)
126 East Lincoln Avenue
Rahway New Jersey 07065
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024 MRK 24 New York Stock Exchange
1.875% Notes due 2026 MRK/26 New York Stock Exchange
3.250% Notes due 2032 MRK/32 New York Stock Exchange
2.500% Notes due 2034 MRK/34 New York Stock Exchange
1.375% Notes due 2036 MRK 36A New York Stock Exchange
3.500% Notes due 2037 MRK/37 New York Stock Exchange
3.700% Notes due 2044 MRK/44 New York Stock Exchange
3.750% Notes due 2054 MRK/54 New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth
company.
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares of common stock outstanding as of the close of business on July 31, 2024: 2,534,809,312

-- 1 of 51 --

Table of Contents
Page No.
PART I FINANCIAL INFORMATION 3
Item 1. Financial Statements 3
Condensed Consolidated Statement of Operations 3
Condensed Consolidated Statement of Comprehensive Income (Loss) 3
Condensed Consolidated Balance Sheet 4
Condensed Consolidated Statement of Cash Flows 5
Notes to Condensed Consolidated Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
Item 3. Quantitative and Qualitative Disclosures about Market Risk 44
Item 4. Controls and Procedures 44
Cautionary Factors That May Affect Future Results 44
PART II OTHER INFORMATION 45
Item 1. Legal Proceedings 45
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45
Item 5. Other Information 45
Item 6. Exhibits 46
Signatures 47

-- 2 of 51 --

Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(Unaudited, $ in millions except per share amounts)
Three Months Ended
June 30, Six Months Ended
June 30,
2024 2023 2024 2023
Sales $ 16,112 $ 15,035 $ 31,887 $ 29,522
Costs, Expenses and Other
Cost of sales 3,745 4,024 7,285 7,951
Selling, general and administrative 2,739 2,702 5,221 5,182
Research and development 3,500 13,321 7,492 17,597
Restructuring costs 80 151 202 218
Other (income) expense, net 42 172 12 259
10,106 20,370 20,212 31,207
Income (Loss) Before Taxes 6,006 (5,335) 11,675 (1,685)
Income Tax Provision 545 637 1,447 1,462
Net Income (Loss) 5,461 (5,972) 10,228 (3,147)
Less: Net Income Attributable to Noncontrolling Interests 6 3 11 7
Net Income (Loss) Attributable to Merck & Co., Inc. $ 5,455 $ (5,975) $ 10,217 $ (3,154)
Basic Earnings (Loss) per Common Share Attributable to Merck & Co.,
Inc. Common Shareholders $ 2.15 $ (2.35) $ 4.03 $ (1.24)
Earnings (Loss) per Common Share Assuming Dilution Attributable to
Merck & Co., Inc. Common Shareholders $ 2.14 $ (2.35) $ 4.02 $ (1.24)
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)
(Unaudited, $ in millions)
Three Months Ended
June 30, Six Months Ended
June 30,
2024 2023 2024 2023
Net Income (Loss) Attributable to Merck & Co., Inc. $ 5,455 $ (5,975) $ 10,217 $ (3,154)
Other Comprehensive Loss Net of Taxes:
Net unrealized gain on derivatives, net of reclassifications 67 145 197 12
Benefit plan net (loss) gain and prior service (cost) credit, net of
amortization (10) (25) (15) (75)
Cumulative translation adjustment (144) (137) (382) (69)
(87) (17) (200) (132)
Comprehensive Income (Loss) Attributable to Merck & Co., Inc. $ 5,368 $ (5,992) $ 10,017 $ (3,286)
The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -

-- 3 of 51 --

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
June 30, 2024 December 31,
2023
Assets
Current Assets
Cash and cash equivalents $ 11,304 $ 6,841
Short-term investments 50 252
Accounts receivable (net of allowance for doubtful accounts of $82 in 2024
and $88 in 2023) 11,642 10,349
Inventories (excludes inventories of $3,456 in 2024 and $3,348 in 2023
classified in Other assets - see Note 6) 6,469 6,358
Other current assets 8,740 8,368
Total current assets 38,205 32,168
Investments 357 252
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,960
in 2024 and $18,266 in 2023 23,221 23,051
Goodwill 21,161 21,197
Other Intangibles, Net 16,984 18,011
Other Assets 12,702 11,996
$ 112,630 $ 106,675
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt $ 3,071 $ 1,372
Trade accounts payable 3,519 3,922
Accrued and other current liabilities 14,712 15,766
Income taxes payable 2,777 2,649
Dividends payable 1,981 1,985
Total current liabilities 26,060 25,694
Long-Term Debt 34,717 33,683
Deferred Income Taxes 876 871
Other Noncurrent Liabilities 7,329 8,792
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2024 and 2023 1,788 1,788
Other paid-in capital 44,362 44,509
Retained earnings 60,187 53,895
Accumulated other comprehensive loss (5,361) (5,161)
100,976 95,031
Less treasury stock, at cost:
1,041,454,052 shares in 2024 and 1,045,470,249 shares in 2023 57,394 57,450
Total Merck & Co., Inc. stockholders’ equity 43,582 37,581
Noncontrolling Interests 66 54
Total equity 43,648 37,635
$ 112,630 $ 106,675
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -

-- 4 of 51 --

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
Six Months Ended
June 30,
2024 2023
Cash Flows from Operating Activities
Net income (loss) $ 10,228 $ (3,147)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Amortization 1,087 1,020
Depreciation 1,029 874
Income from investments in equity securities, net (200) (274)
Charge for the acquisition of Harpoon Therapeutics, Inc. 656 —
Charge for the acquisition of Prometheus Biosciences, Inc. — 10,217
Charge for the acquisition of Imago BioSciences, Inc. — 1,192
Deferred income taxes (232) (632)
Share-based compensation 379 314
Other 174 5
Net changes in assets and liabilities (4,394) (4,526)
Net Cash Provided by Operating Activities 8,727 5,043
Cash Flows from Investing Activities
Capital expenditures (1,652) (1,972)
Purchases of securities and other investments (64) (587)
Proceeds from sales of securities and other investments 320 785
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired (746) —
Acquisition of Prometheus Biosciences, Inc., net of cash acquired — (10,705)
Acquisition of Imago BioSciences, Inc., net of cash acquired — (1,327)
Other (303) 4
Net Cash Used in Investing Activities (2,445) (13,802)
Cash Flows from Financing Activities
Net change in short-term borrowings — 1,937
Proceeds from issuance of debt 3,600 5,946
Payments on debt (751) (1,751)
Dividends paid to stockholders (3,936) (3,738)
Purchases of treasury stock (373) (487)
Proceeds from exercise of stock options 160 112
Other (298) (315)
Net Cash (Used in) Provided by Financing Activities (1,598) 1,704
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (220) (6)
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 4,464 (7,061)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of
$68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets) 6,909 12,773
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $69
and $52 at June 30, 2024 and 2023, respectively, included in Other current assets) $ 11,373 $ 5,712
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -

-- 5 of 51 --

1. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the
Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information
and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated
financial statements are not included herein. These interim statements should be read in conjunction with the audited financial
statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2024.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full
year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included
and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the
current year presentation.
Recently Adopted Accounting Standard
In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly
formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended
guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations
guidance. The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1,
2025, however existing joint ventures have the option to apply the guidance retrospectively. The Company adopted the guidance
effective July 1, 2024 on a prospective basis. There was no impact to the Company’s consolidated financial statements upon
adoption.
Recently Issued Accounting Standards Not Yet Adopted
In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements,
primarily through expanded disclosures for significant segment expenses. The guidance is effective for annual periods beginning
in 2024, and interim periods beginning in 2025. The guidance will result in incremental disclosures within the footnotes to the
Company’s financial statements.
In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by
requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes
paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax
disclosures by removing certain previously required disclosures. The guidance is effective beginning with 2025 annual reporting.
Early adoption is permitted. The guidance will result in incremental disclosures within the footnotes to the Company’s financial
statements.
2. Acquisitions, Divestitures, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research
collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include
upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements
contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include
option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which
may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets.
Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are
not significant when compared with the Company’s financial results.
2024 Transactions
In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco) for approximately
$1.3 billion. The Elanco aqua business consists of an innovative portfolio of medicines and vaccines, nutritionals and
supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility
in Chile. The acquisition broadens Animal Health’s aqua portfolio with products such as Clynav, a new generation DNA-based
vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition
also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water
vaccine portfolio. In addition to these products, the DNA-based vaccine technology that is a part of the business has the potential
to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The Company is in the
process of determining the preliminary fair value of assets acquired, liabilities assumed and total consideration transferred in this
transaction, which will be accounted for as a business combination.
Also in July 2024, Merck acquired Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused
biotechnology company for an upfront payment of $1.3 billion. The acquisition agreement also provides for a further $1.7 billion
in potential developmental, regulatory and sales-based milestone payments. EyeBio’s development work focused on candidates
for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases.
EyeBio’s lead candidate, Restoret/MK-3000 (formerly EYE103), is an investigational, potentially first-in-class tetravalent, tri-
specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, which is in clinical
development for the treatment of diabetic macular edema and neovascular age-related macular degeneration. The transaction
Notes to Condensed Consolidated Financial Statements (unaudited)
- 6 -

-- 6 of 51 --

will be accounted for as an asset acquisition since Restoret/MK-3000 accounted for substantially all of the fair value of the gross
assets acquired (excluding cash and deferred income taxes). Merck will record a charge of approximately $1.3 billion to
Research and development expenses in the third quarter of 2024.
Additionally in July 2024, Merck and Orion Corporation (Orion) announced the mutual exercise of an option to convert
the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an
investigational cytochrome P450 11A1 (CYP11A1) inhibitor, and other candidates targeting CYP11A1, into an exclusive global
license for Merck. With the exercise of the option, Merck will assume full responsibility for all past and future development and
commercialization expenses associated with the candidates covered by the original agreement. In addition, Orion will become
eligible to receive developmental milestone payments up to $30 million, regulatory milestone payments up to $625 million and
sales-based milestone payments up to $975 million, as well as annually tiered royalty payments ranging from a low double-digit
rate up to a rate in the low twenties on net sales for any commercialized licensed product. Orion will retain responsibility for the
manufacture of clinical and commercial supply for Merck. No payment was associated with the exercise of the option. The
exclusive global license is expected to become effective in the third quarter of 2024, but is subject to certain conditions, including
approval under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions.
In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company
developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients
suffering from cancer and other diseases, for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead
candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch
ligand that is expressed at high levels in small-cell lung cancer (SCLC) and neuroendocrine tumors. MK-6070 is currently being
evaluated as monotherapy in a Phase 1/2 clinical trial in certain patients with advanced cancers associated with expression of
DLL3. The study is also evaluating MK-6070 in combination with atezolizumab in certain patients with SCLC. The transaction
was accounted for as an asset acquisition since MK-6070 represented substantially all of the fair value of the gross assets
acquired (excluding cash and deferred income taxes). Merck recorded net assets of $165 million, as well as a charge of $656
million to Research and development expenses in the first six months of 2024 related to the transaction. There are no future
contingent payments associated with the acquisition.
2023 Transactions
In June 2023, Merck acquired Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company
pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment of immune-mediated diseases. Total consideration paid of $11.0 billion included
$1.2 billion of costs to settle share-based equity awards (including $700 million to settle unvested equity awards). Prometheus’
lead candidate, tulisokibart (MK-7240, formerly PRA023), is a humanized monoclonal antibody directed to tumor necrosis factor-
like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Tulisokibart is being developed for the treatment
of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. A Phase 3 clinical
trial evaluating tulisokibart for ulcerative colitis commenced in 2023. The transaction was accounted for as an acquisition of an
asset since tulisokibart accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred
income taxes). Merck recorded net assets of $877 million, including cash of $368 million, investments of $296 million, deferred
tax assets of $218 million and other net liabilities of $5 million, as well as a charge of $10.2 billion to Research and development
expenses in the second quarter and first six months of 2023 related to the transaction. There are no future contingent payments
associated with the acquisition.
In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed
a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research,
development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for
the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed
and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was
recorded as a charge to Research and development expenses in the first six months of 2023. In October 2023, Merck notified
Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified
Kelun-Biotech it was terminating an additional candidate under the agreement. In July 2024, Merck notified Kelun-Biotech that it
was exercising an existing license option for one of the candidates under the agreement, granting Merck a license for the
development, manufacture and commercialization worldwide excluding China. There are now three candidates licensed under
the original agreement and one candidate for which the license option remains unexercised. Merck will pay Kelun-Biotech
$38 million in connection with the July option exercise, following which Kelun-Biotech remains eligible to receive future
contingent payments aggregating up to $540 million in development-related payments, $1.5 billion in regulatory milestones, and
$3.1 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the
remaining option ADC and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive
tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC
product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company
developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion
(including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs.
Imago’s lead candidate, bomedemstat (MK-3543, formerly IMG-7289), is an investigational orally available lysine-specific
demethylase 1 inhibitor currently being evaluated in multiple clinical trials for the treatment of essential thrombocythemia,
myelofibrosis, and polycythemia vera, in addition to other indications. A Phase 3 clinical trial evaluating bomedemstat for the
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 7 -

-- 7 of 51 --

treatment of certain patients with essential thrombocythemia is underway. The transaction was accounted for as an asset
acquisition since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and
deferred income taxes). Merck recorded net assets of $219 million, as well as a charge of $1.2 billion to Research and
development expenses in the first six months of 2023 related to the transaction. There are no future contingent payments
associated with the acquisition.
Spin-Off of Organon & Co.
In connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Organon entered into a series of interim
operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in
connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market,
import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to
Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of June 30, 2024, only one
jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of
manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the
condensed consolidated statement of operations for the above MSAs include sales of $93 million and $96 million and related
cost of sales of $92 million and $101 million for the second quarter of 2024 and 2023, respectively, and sales of $201 million and
$191 million and related cost of sales of $202 million and $208 million for the first six months of 2024 and 2023, respectively. The
amounts due from Organon for all spin-off related agreements were $557 million and $632 million at June 30, 2024 and
December 31, 2023, respectively, and are reflected in Other current assets. The amounts due to Organon under these
agreements were $102 million and $598 million at June 30, 2024 and December 31, 2023, respectively, and are included in
Accrued and other current liabilities.
3. Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce
and market products together with its collaborative partners. Both parties in these arrangements are active participants and
exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s
more significant collaborative arrangements are discussed below.
AstraZeneca PLC
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-
develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and
AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines,
Keytruda (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo
(selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck share the development and
commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are
shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza
and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development
costs associated with the collaboration as part of Research and development expenses. Reimbursements received from
AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-
year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca
related to the successful achievement of sales-based and regulatory milestones.
In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-
based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained
accrued at June 30, 2024) and a corresponding increase to the intangible asset related to Lynparza. Potential future sales-based
milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this
time. Lynparza received regulatory approvals triggering capitalized milestone payments from Merck to AstraZeneca of
$245 million and $105 million in the first six months of 2024 and 2023, respectively (each of which had been previously accrued
for). In the second quarter of 2024, the partners agreed that no future regulatory milestone payments from Merck to AstraZeneca
are likely under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone
payments) was $1.3 billion at June 30, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its
estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 8 -

-- 8 of 51 --

Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Alliance revenue - Lynparza $ 317 $ 310 $ 609 $ 585
Alliance revenue - Koselugo 37 25 75 48
Total alliance revenue $ 354 $ 335 $ 684 $ 633
Cost of sales (1) 82 78 163 148
Selling, general and administrative 43 51 82 98
Research and development 18 22 38 43
($ in millions)
June 30,
2024 December
31, 2023
Receivables from AstraZeneca included in Other current assets $ 349 $ 341
Payables to AstraZeneca included in Accrued and other current liabilities (2) 615 256
Payables to AstraZeneca included in Other Noncurrent Liabilities (2) — 600
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Eisai Co., Ltd.
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and
co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the
agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with
Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and
Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and
commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in
accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred
solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon
caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for
certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful
achievement of sales-based and regulatory milestones.
In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a
$125 million sales-based milestone payment from Merck to Eisai. Similarly, in the third quarter of 2023 an additional $125 million
sales-based milestone payment to Eisai was deemed by the Company to be probable of payment. Accordingly, Merck recorded
$250 million of liabilities for these payments (one of which was paid in the second quarter of 2023 and the other was paid in the
second quarter of 2024) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized
$72 million and $81 million of cumulative amortization catch-up expense related to the recognition of these milestones in the first
and third quarters of 2023, respectively. Potential future sales-based milestone payments of $2.3 billion have not yet been
accrued as they are not deemed by the Company to be probable at this time. There are no regulatory milestone payments
remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone
payments) was $563 million at June 30, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its
estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 9 -

-- 9 of 51 --

Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Alliance revenue - Lenvima $ 249 $ 242 $ 504 $ 474
Cost of sales (1) 60 57 121 183
Selling, general and administrative 41 48 80 99
Research and development 6 17 13 56
($ in millions)
June 30,
2024 December
31, 2023
Receivables from Eisai included in Other current assets $ 245 $ 226
Payables to Eisai included in Accrued and other current liabilities (2) — 125
(1) Represents amortization of capitalized milestone payments. Amount in the first six months of 2023 includes $72 million of cumulative amortization catch-up
expense as noted above.
(2) Represents an accrued milestone payment.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market
and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The
two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer
commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck
commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and
profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance
revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are
product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in
Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful
achievement of sales-based milestones. There are no sales-based milestone payments remaining under this collaboration.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as
capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-
based milestone payment that was attributed to Verquvo) were $445 million and $47 million, respectively, at June 30, 2024 and
are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for
Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Alliance revenue - Adempas/Verquvo $ 106 $ 68 $ 203 $ 167
Net sales of Adempas recorded by Merck 72 65 142 125
Net sales of Verquvo recorded by Merck 9 9 16 16
Total sales $ 187 $ 142 $ 361 $ 308
Cost of sales (1) 61 56 123 113
Selling, general and administrative 26 34 59 67
Research and development 28 25 55 50
($ in millions)
June 30,
2024 December
31, 2023
Receivables from Bayer included in Other current assets $ 170 $ 156
Payables to Bayer included in Accrued and other current liabilities 81 80
(1) Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a
collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the
treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and
related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received
multiple additional authorizations.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 10 -

-- 10 of 51 --

Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent
payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also
provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net
sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related
costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the
partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of
profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Net sales of Lagevrio recorded by Merck $ 110 $ 203 $ 460 $ 595
Cost of sales (1) 96 193 287 414
Selling, general and administrative 16 24 32 51
Research and development 7 10 2 26
($ in millions)
June 30,
2024 December
31, 2023
Receivables from Ridgeback included in Other current assets $ 8 $ —
Payables to Ridgeback included in Accrued and other current liabilities (2) 24 113
(1) Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2) Includes accrued royalties.
Daiichi Sankyo
In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for
three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd)
(MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of
clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments.
The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where
Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.
Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These
payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be
refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the
agreement provides for a continuation payment of $750 million related to patritumab deruxtecan due from Merck in October 2024
and a continuation payment of $750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck does not
make the continuation payments on the dates noted for either patritumab deruxtecan and/or raludotatug deruxtecan, the rights
for the applicable program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by
Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional
$5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones. In conjunction with this
transaction, Merck recorded an aggregate pretax charge of $5.5 billion to Research and development expenses in the fourth
quarter of 2023 for the $4.0 billion of upfront payments and the $1.5 billion of continuation payments.
Merck and Daiichi Sankyo equally share research and development costs, except for raludotatug deruxtecan, where
Merck is responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of
development costs associated with the collaboration as part of Research and development expenses. Following regulatory
approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the
companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive
rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and
commercialization costs, as alliance revenue.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 11 -

-- 11 of 51 --

Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Selling, general and administrative $ 14 $ — $ 16 $ —
Research and development 65 — 133 —
($ in millions)
June 30,
2024 December
31, 2023
Payables to Daiichi Sankyo included in Accrued and other current liabilities $ 801 $ 800
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities 750 750
Moderna, Inc.
In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational
individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc.
(Moderna). V940 (mRNA-4157) is currently being evaluated in combination with Keytruda in multiple Phase 3 clinical trials.
Merck and Moderna will share costs and any profits equally under this worldwide collaboration. Merck records its share of
development costs associated with the collaboration as part of Research and development expenses. Any reimbursements
received from Moderna for research and development expenses are recognized as reductions to Research and development
costs. Merck has also capitalized certain of the shared costs, which aggregated $135 million at June 30, 2024 and will be
amortized over the assets’ estimated useful lives.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Selling, general and administrative $ 4 $ 1 $ 6 $ 2
Research and development 93 60 162 86
($ in millions)
June 30,
2024 December
31, 2023
Payables to Moderna included in Accrued and other current liabilities $ 73 $ 63
Bristol-Myers Squibb Company
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being
commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S.,
Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for
additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-
promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is
reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced
by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck
is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this
collaboration, consisting of royalties (recorded within Sales) was $90 million and $161 million in the second quarter and first six
months of 2024, respectively, compared with $47 million and $90 million in the second quarter and first six months of 2023,
respectively.
4. Restructuring
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to
continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new
modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency.
The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031,
with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0
billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of
facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down
costs. The Company recorded total pretax costs of $177 million and $422 million in the second quarter and first six months of
2024, respectively, related to the 2024 Restructuring Program, bringing total cumulative pretax costs incurred through June 30,
2024 to $613 million.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide
initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate
footprint. The Company recorded total pretax costs of $236 million and $333 million in the second quarter and first six months of
2023, respectively, related to the 2019 Restructuring Program. The actions under the 2019 Restructuring Program were
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 12 -

-- 12 of 51 --

substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are now being accounted for as
part of the 2024 Restructuring Program.
For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to the restructuring programs by type of cost:
Three Months Ended June 30, 2024 Six Months Ended June 30, 2024
($ in millions)
Accelerated
Depreciation Separation
Costs Other Exit
Costs Total Accelerated
Depreciation Separation
Costs Other Total
2024 Restructuring Program
Cost of sales $ 66 $ — $ — $ 66 $ 131 $ — $ 51 $ 182
Selling, general and
administrative — — 31 31 — — 36 36
Research and development — — — — — — 2 2
Restructuring costs — 19 61 80 — 111 91 202
$ 66 $ 19 $ 92 $ 177 $ 131 $ 111 $ 180 $ 422
Three Months Ended June 30, 2023 Six Months Ended June 30, 2023
($ in millions)
Accelerated
Depreciation Separation
Costs Other Exit
Costs Total Accelerated
Depreciation Separation
Costs Other Total
2019 Restructuring Program
Cost of sales $ 22 $ — $ 10 $ 32 $ 43 $ — $ 18 $ 61
Selling, general and
administrative — — 52 52 — — 53 53
Research and development — — 1 1 — — 1 1
Restructuring costs — 110 41 151 — 151 67 218
$ 22 $ 110 $ 104 $ 236 $ 43 $ 151 $ 139 $ 333
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment
to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation
expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or
divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring
actions. All the sites will continue to operate up through the respective closure dates and, since future undiscounted cash flows
are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of
the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be
adjusted to reflect changes resulting from regulatory or other factors.
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which
were probable and could be reasonably estimated.
Other exit costs in 2024 and 2023 include asset abandonment, facility shut-down and other related costs, as well as
pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain
employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based
compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the six
months ended June 30, 2024:
($ in millions)
Accelerated
Depreciation Separation
Costs Other Exit
Costs Total
Restructuring reserves January 1, 2024 $ — $ 681 $ 31 $ 712
Expenses 131 111 180 422
(Payments) receipts, net — (132) (73) (205)
Non-cash activity (131) — (111) (242)
Restructuring reserves June 30, 2024 $ — $ 660 $ 27 $ 687
5. Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its
earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial
instruments, including derivative instruments.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 13 -

-- 13 of 51 --

A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign
exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well
as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging
programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign
exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange
rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the
euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign
currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its
planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the
portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales
hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign
exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated
transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions)
in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in
either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a
hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the
unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified
into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow
hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The
cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed
Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the
effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other
than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the
effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk
management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange.
Merck principally utilizes forward exchange contracts to offset the effects of foreign exchange on exposures when it is deemed
economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign
exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi).
The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net.
Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and
liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These
differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception
of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated
Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations
against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign
operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI
and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company
excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness
(excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in
earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than
using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed
Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. A portion of the Company’s senior
unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a
foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated
debt instruments are included in foreign currency translation adjustment within OCI.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 14 -

-- 14 of 51 --

The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Income
are shown below:
Amount of Pretax (Gain) Loss Recognized in
Other Comprehensive Income (1)
Amount of Pretax Loss Recognized in Other
(income) expense, net for Amounts Excluded
from Effectiveness Testing
Three Months Ended
June 30, Six Months Ended
June 30, Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023 2024 2023 2024 2023
Net Investment Hedging Relationships
Foreign exchange contracts $ 5 $ — $ 3 $ 1 $ (1) $ — $ (1) $ 1
Euro-denominated notes (34) 21 (96) 73 — — — —
(1) No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net
exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and,
in general, does not leverage any of its investment activities that would put principal at risk.
At June 30, 2024, the Company was a party to six pay-floating, receive-fixed interest rate swap contracts designated
as fair value hedges of a portion of fixed-rate notes as detailed in the table below.
June 30, 2024
($ in millions) Par Value of Debt
Number of Interest
Rate Swaps Held
Total Swap Notional
Amount
4.50% notes due 2033 $ 1,500 6 $ 1,500
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes
in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to
changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap
contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of
Cash Flows.
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to
cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged
Liabilities
Cumulative Amount of Fair Value
Hedging Adjustment Increase
Included in the Carrying Amount
($ in millions) June 30, 2024 December 31,
2023 June 30, 2024 December 31,
2023
Balance Sheet Caption
Long-Term Debt $ 1,521 $ 1,056 $ 30 $ 56
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives
that are designated as hedging instruments and those that are not designated as hedging instruments:
June 30, 2024 December 31, 2023
Fair Value of Derivative U.S. Dollar
Notional
Fair Value of Derivative U.S. Dollar
Notional	($ in millions) Asset Liability Asset Liability
Derivatives Designated as
Hedging Instruments Balance Sheet Caption
Interest rate swap contracts Other Assets $ 30 $ — $ 1,500 $ 57 $ — $ 1,000
Foreign exchange contracts Other current assets 226 — 8,830 106 — 6,138
Foreign exchange contracts Other Assets 46 — 2,052 26 — 1,929
Foreign exchange contracts Accrued and other current liabilities — 4 901 — 76 3,680
Foreign exchange contracts Other Noncurrent Liabilities — 1 230 — 1 7
302 5 13,513 189 77 12,754
Derivatives Not Designated
as Hedging Instruments Balance Sheet Caption
Foreign exchange contracts Other current assets 187 — 8,723 153 — 9,693
Foreign exchange contracts Other Assets 2 — 22 — — —
Foreign exchange contracts Accrued and other current liabilities — 135 10,818 — 162 8,104
Foreign exchange contracts Other Noncurrent Liabilities — 2 22 — — —
189 137 19,585 153 162 17,797
$ 491 $ 142 $ 33,098 $ 342 $ 239 $ 30,551
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance
Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 15 -

-- 15 of 51 --

Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master
netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral
exchanged per the master agreements and related credit support annexes:
June 30, 2024 December 31, 2023
($ in millions) Asset Liability Asset Liability
Gross amounts recognized in the condensed consolidated balance sheet $ 491 $ 142 $ 342 $ 239
Gross amounts subject to offset in master netting arrangements not offset in the condensed
consolidated balance sheet (114) (114) (215) (215)
Cash collateral received (123) — (3) —
Net amounts $ 254 $ 28 $ 124 $ 24
The table below provides information regarding the location and amount of pretax gains and losses of derivatives
designated in fair value or cash flow hedging relationships:
Three Months Ended June 30, Six Months Ended June 30,
($ in millions) 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023
Financial Statement Caption in which
Effects of Fair Value or Cash Flow
Hedges are Recorded Sales Other (income)
expense, net (1)
Other
comprehensive
income (loss) Sales Other (income)
expense, net (1)
Other
comprehensive
income (loss)
$ 16,112 $ 15,035 $ 42 $ 172 $ (87) $ (17) $ 31,887 $ 29,522 $ 12 $ 259 $ (200) $ (132)
(Gain) loss on fair value hedging
relationships:
Interest rate swap contracts
Hedged items — — 4 — — — — — (26) — — —
Derivatives designated as hedging
instruments — — (4) — — — — — 27 — — —
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain recognized in OCI on
derivatives — — — — 139 194 — — — — 348 128
Increase in Sales as a result of AOCL
reclassifications 54 24 — — (54) (24) 98 125 — — (98) (125)
Interest rate contracts
Amount of gain recognized in Other
(income) expense, net on derivatives — — — — — — — — (1) (1) — —
Amount of gain recognized in OCI on
derivatives — — — — — 13 — — — — (1) 13
(1) Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as
hedging instruments:
Amount of Derivative Pretax (Gain) Loss
Recognized in Income
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Derivatives Not Designated as Hedging Instruments Income Statement Caption
Foreign exchange contracts (1) Other (income) expense, net $ 9 $ (41) $ 75 $ (28)
Foreign exchange contracts (2) Sales (10) (5) (20) (3)
(1) These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to
changes in foreign currency exchange rates.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
At June 30, 2024, the Company estimates $190 million of pretax net unrealized gains on derivatives maturing within
the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to
Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are
ultimately determined by actual foreign exchange rates at maturity.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 16 -

-- 16 of 51 --

Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
June 30, 2024 December 31, 2023
Amortized
Cost
Gross Unrealized Fair
Value Amortized
Cost
Gross Unrealized Fair
Value	($ in millions) Gains Losses Gains Losses
U.S. government and agency securities $ 77 $ — $ — $ 77 $ 72 $ — $ — $ 72
Commercial paper 50 — — 50 252 — — 252
Corporate notes and bonds — — — — 13 — — 13
Total debt securities $ 127 $ — $ — $ 127 $ 337 $ — $ — $ 337
Publicly traded equity securities (1) 1,026 764
Total debt and publicly traded equity
securities $ 1,153 $ 1,101
(1) Unrealized net losses (gains) of $8 million and $(125) million were recorded in Other (income) expense, net in the second quarter and first six months of 2024,
respectively, on equity securities still held at June 30, 2024. Unrealized net losses (gains) of $71 million and $(267) million were recorded in Other (income)
expense, net in the second quarter and first six months of 2023, respectively, on equity securities still held at June 30, 2023.
At June 30, 2024 and June 30, 2023, the Company also had $936 million and $949 million, respectively, of equity
investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these
equity investments based on favorable observable price changes from transactions involving similar investments of the same
investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income)
expense, net. During the first six months of 2024, the Company recorded unrealized gains of $61 million and unrealized losses of
$5 million related to certain of these equity investments still held at June 30, 2024. During the first six months of 2023, the
Company recorded unrealized gains of $3 million and unrealized losses of $23 million related to certain of these equity
investments still held at June 30, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable
price changes for investments in equity investments without readily determinable fair values still held at June 30, 2024 were $355
million and $69 million, respectively.
At June 30, 2024 and June 30, 2023, the Company also had $278 million and $622 million, respectively, recorded in
Other Assets for equity securities held through ownership interests in investment funds. (Gains) losses recorded in Other
(income) expense, net relating to these investment funds were $(7) million and $105 million for the second quarter of 2024 and
2023, respectively, and were $(5) million and $(27) million for the first six months of 2024 and 2023, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit
price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and
minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value
with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other
inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or
liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those
whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant
unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or
estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the
categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 17 -

-- 17 of 51 --

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements Using Fair Value Measurements Using
Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total
($ in millions) June 30, 2024 December 31, 2023
Assets
Investments
Commercial paper $ — $ 50 $ — $ 50 $ — $ 252 $ — $ 252
Publicly traded equity securities 357 — — 357 252 — — 252
357 50 — 407 252 252 — 504
Other assets (1)
U.S. government and agency
securities 77 — — 77 72 — — 72
Corporate notes and bonds — — — — 13 — — 13
Publicly traded equity securities (2) 669 — — 669 512 — — 512
746 — — 746 597 — — 597
Derivative assets (3)
Forward exchange contracts — 278 — 278 — 202 — 202
Purchased currency options — 183 — 183 — 83 — 83
Interest rate swaps — 30 — 30 — 57 — 57
— 491 — 491 — 342 — 342
Total assets $ 1,103 $ 541 $ — $ 1,644 $ 849 $ 594 $ — $ 1,443
Liabilities
Other liabilities
Contingent consideration $ — $ — $ 225 $ 225 $ — $ — $ 354 $ 354
Derivative liabilities (3)
Forward exchange contracts — 115 — 115 — 239 — 239
Written currency options — 27 — 27 — — — —
— 142 — 142 — 239 — 239
Total liabilities $ — $ 142 $ 225 $ 367 $ — $ 239 $ 354 $ 593
(1) Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2) Balance at June 30, 2024 includes securities with a fair value of $285 million, which were subject to a contractual sale restriction that expired in July 2024.
(3) The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects
of which were not significant.
As of June 30, 2024 and December 31, 2023, Cash and cash equivalents included $10.5 billion and $6.0 billion of
cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with
business combinations is as follows:
($ in millions) 2024 2023
Fair value January 1 $ 354 $ 456
Changes in estimated fair value (1) (3) 10
Payments (126) (117)
Fair value June 30 (2) $ 225 $ 349
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) Balance at June 30, 2024, includes $131 million of current liabilities, all of which relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part
of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the
joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-
adjusted discount rate to present value the cash flows.
The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described
above.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are
reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at June 30, 2024, was $33.5
billion compared with a carrying value of $37.8 billion and at December 31, 2023, was $32.0 billion compared with a carrying
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 18 -

-- 18 of 51 --

value of $35.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the
fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government
issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a
concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality
standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are
primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the
financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit
profile. The Company also continues to monitor global economic conditions, including the volatility associated with international
sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell
accounts receivable. The Company factored $2.9 billion and $3.0 billion of accounts receivable as of June 30, 2024 and
December 31, 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The
cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of
Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments
related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. As of
June 30, 2024 and December 31, 2023, the Company had collected $42 million and $44 million, respectively, on behalf of the
financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash
within Accrued and other current liabilities. The net cash flows related to these collections are reported as financing activities in
the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master
agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support
annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative
assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the
Company from various counterparties was $123 million and $3 million at June 30, 2024 and December 31, 2023, respectively.
The obligation to return such collateral is recorded in Accrued and other current liabilities.
6. Inventories
Inventories consisted of:
($ in millions) June 30, 2024 December 31,
2023
Finished goods $ 1,889 $ 1,954
Raw materials and work in process 8,456 8,037
Supplies 267 277
Total 10,612 10,268
Decrease to LIFO cost (687) (562)
$ 9,925 $ 9,706
Recognized as:
Inventories $ 6,469 $ 6,358
Other Assets 3,456 3,348
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories.
At June 30, 2024 and December 31, 2023, these amounts included $3.2 billion and $2.6 billion, respectively, of inventories not
expected to be sold within one year. In addition, these amounts included $250 million and $790 million at June 30, 2024 and
December 31, 2023, respectively, of inventories produced in preparation for product launches.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 19 -

-- 19 of 51 --

7. Long-Term Debt
In May 2024, MSD Netherlands Capital B.V., a wholly-owned finance subsidiary of Merck, completed a registered
public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of €850 million of 3.25%
senior notes due 2032, €850 million of 3.50% senior notes due 2037, €850 million of 3.70% senior notes due 2044 and
€850 million of 3.75% senior notes due 2054 (collectively, the Euronotes). The Company has fully and unconditionally
guaranteed all of MSD Netherlands Capital B.V.’s obligations under the Euronotes and no other subsidiary of the Company will
guarantee these obligations. MSD Netherlands Capital B.V. is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of
Regulation S-X of the Exchange Act, with no assets or operations other than those related to the issuance, administration and
repayment of the Euronotes. The financial condition, results of operations and cash flows of MSD Netherlands Capital B.V. are
consolidated in the financial statements of the Company. The net cash proceeds from the offering were used for general
corporate purposes.
8. Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business,
including product liability, intellectual property, and commercial litigation, as well as certain additional matters including
governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be
material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is
unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other
factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any
potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the
litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect
on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount
can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information
becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers
such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually
significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred
in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and
availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost
of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no
insurance for most product liabilities.
Product Liability Litigation
Dr. Scholl’s Foot Powder
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged
exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold
as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were
exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of June 30, 2024, approximately 290 cases
were pending against Merck in various state courts.
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human
Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent
Vaccine, Recombinant). As of June 30, 2024, approximately 210 cases were filed and pending against Merck in either federal or
state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination
with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the
U.S. Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts
nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial
proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. One state court action in Los
Angeles County is scheduled to commence trial on October 7, 2024. As previously disclosed, there are fewer than 15 product
liability cases pending outside the U.S.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 20 -

-- 20 of 51 --

Governmental Proceedings
Civil Investigative Demand
In June 2024, Merck received a Civil Investigative Demand (CID) from the U.S. Department of Justice, pursuant to a
False Claims Act investigation, seeking documents and materials related to Steglatro, Januvia and certain related drugs. The
CID states that it is investigating Merck’s price reporting under the Medicaid Drug Rebate Program as well as compliance with
anti-kickback requirements in connection with patient assistance programs. The Company is cooperating with the investigation.
Other Matters
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their
operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other
multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy
is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary
investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may
include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation
activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and
similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should
those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications
(ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to
the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement
lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries.
The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting
to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes,
which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products
acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment
charges.
Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph
IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies had filed applications to
the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and
December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the
Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated.
The West Virginia case was jointly dismissed with prejudice in August 2022 in favor of proceeding in New Jersey. The remaining
defendants in the New Jersey action stipulated to infringement of the asserted claims and withdrew all remaining claims and
defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December
2022.
As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck’s favor. The
court held that Merck’s calculation of PTE for the sugammadex patent covering the compound is not invalid and that the U.S.
Patent & Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck’s U.S. patent
protection for Bridion through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey
issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until
January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.
In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is
currently pending.
While the New Jersey action was pending, the Company settled with five generic companies providing that these
generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any
applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two
generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District
of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the
Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this
company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric
exclusivity.
On February 5, 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act
notifying the Company that Hikma Pharmaceuticals USA Inc. (Hikma) has filed an application to the FDA seeking pre-patent
expiry approval to sell a generic version of Bridion Injection. On March 15, 2024, the Company filed a patent infringement lawsuit
in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30
months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an
adverse court decision, if any, whichever may occur earlier. Expiration of the patent, and any potentially applicable pediatric
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 21 -

-- 21 of 51 --

exclusivity, will occur earlier than expiry of the 30-month stay. On April 16, 2024, the district court stayed the case during the
pendency of the Federal Circuit appeal.
Januvia, Janumet, Janumet XR — As previously disclosed, the FDA granted pediatric exclusivity with respect to
Januvia (sitagliptin), Janumet (sitagliptin/metformin HCI), and Janumet XR (sitagliptin and metformin HCl extended-release),
which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book.
Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However,
Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering
certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/
polymorph patent).
As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of
generic forms of Januvia and Janumet along with paragraph IV certifications challenging the validity of the 2027 salt/polymorph
patent. The Company responded by filing infringement suits which have all been settled. The Company has settled with a total of
26 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the
market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in
July 2026 or earlier under certain circumstances.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware
against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that
lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking
approval of a form of sitagliptin that is a different form than that used in Januvia. In December 2022, the parties reached
settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically
substitutable product.
In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying
the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or
enforceable claim of any of the patents listed in FDA’s Orange Book for Janumet will be infringed by the proposed Zydus product.
In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product
containing a different form of sitagliptin than that used in Janumet. In November 2023, the Company received a Paragraph IV
Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/
metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval
of a non-automatically substitutable version containing a different form of sitagliptin than that used in Janumet XR.
As a result of these settlement agreements related to the later expiring 2027 salt/polymorph patent directed to the
specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in
the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although Zydus has received
FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin
products.
Supplementary Protection Certificates (SPCs) for Janumet expired in April 2023 for the majority of European
countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In
February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could
determine the validity of the Janumet SPCs in Europe, for which an oral hearing was held in March 2023 and an Advocate
General Opinion was received on June 6, 2024, with a decision expected later in 2024. If the CJEU renders a decision that
negatively impacts the validity of the Janumet SPCs throughout Europe, generic companies that were prevented from launching
products during the SPC period in certain European countries may have an action for damages. Those countries include
Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the
Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of
the Janumet SPC.
In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and
Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture,
sale and offer for sale of the Defendants’ sitagliptin dihydrogen phosphate product, while the Company’s patents and patent term
extensions are in force. The lawsuit is in response to the Defendants’ application for marketing authorization to sell a generic
sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved on August 15, 2023. Merck asserts that the
Defendants’ activity infringes a patent term extension associated with Merck’s patent directed to the sitagliptin compound patent.
Keytruda — As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins
University (JHU) in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration
between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and
JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the
genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents
citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these
patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for
breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and
May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand
for damages. Between November 30, 2023, and March 13, 2024, the Company filed inter partes review (IPR) petitions with the
United States Patent & Trademark Office Patent Trial and Appeal Board (PTAB), challenging the validity of all nine patents
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 22 -

-- 22 of 51 --

asserted in the case. On June 13, 2024, the PTAB instituted a review of one of the asserted patents. The additional IPR petitions
and institution decisions are all still pending. On July 1, 2024, the District Court granted Merck’s motion to stay the case in its
entirety pending the outcome of the PTAB proceeding.
Lynparza — In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under
the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-
patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company
filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit,
which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025
or until an adverse court decision, if any, whichever may occur earlier.
In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the
Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. (Sandoz) has filed an application to the FDA seeking pre-patent
expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a
patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts
one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an
adverse court decision, if any, whichever may occur earlier.
In May 2024, AstraZeneca Pharmaceuticals LP received a third Paragraph IV Certification Letter under the Hatch-
Waxman Act notifying AstraZeneca that Cipla USA, Inc. and Cipla Limited (collectively, Cipla) filed an application to the FDA
seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In June 2024, AstraZeneca and the
Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Cipla. This lawsuit,
which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until November
2026 or until an adverse court decision, if any, whichever may occur earlier.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual
property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the
likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to
be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and
reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the
actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the
scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials; and
the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the
associated litigation. The amount of legal defense reserves as of June 30, 2024 and December 31, 2023 of approximately $215
million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be
incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in
the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company
will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to
increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 23 -

-- 23 of 51 --

9. Equity
Three Months Ended June 30,
Common Stock Other
Paid-In
Capital Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury Stock Non-
controlling
Interests Total
($ and shares in millions except per share
amounts) Shares Par Value Shares Cost
Balance at April 1, 2023 3,577 $ 1,788 $ 44,467 $ 62,039 $ (4,883) 1,040 $ (56,577) $ 71 $ 46,905
Net loss attributable to Merck & Co., Inc. — — — (5,975) — — — — (5,975)
Other comprehensive loss, net of taxes — — — — (17) — — — (17)
Cash dividends declared on common stock
($0.73 per share) — — — (1,866) — — — — (1,866)
Treasury stock shares purchased — — — — — 3 (338) — (338)
Share-based compensation plans and other — — (248) — — (5) 303 — 55
Net income attributable to noncontrolling
interests — — — — — — — 3 3
Distributions attributable to noncontrolling
interests — — — — — — — (25) (25)
Balance at June 30, 2023 3,577 $ 1,788 $ 44,219 $ 54,198 $ (4,900) 1,038 $ (56,612) $ 49 $ 38,742
Balance at April 1, 2024 3,577 $ 1,788 $ 44,598 $ 56,697 $ (5,274) 1,044 $ (57,445) $ 60 $ 40,424
Net income attributable to Merck & Co., Inc. — — — 5,455 — — — — 5,455
Other comprehensive loss, net of taxes — — — — (87) — — — (87)
Cash dividends declared on common stock
($0.77 per share) — — — (1,965) — — — — (1,965)
Treasury stock shares purchased — — — — — 2 (251) — (251)
Share-based compensation plans and other — — (236) — — (5) 302 — 66
Net income attributable to noncontrolling
interests — — — — — — — 6 6
Balance at June 30, 2024 3,577 $ 1,788 $ 44,362 $ 60,187 $ (5,361) 1,041 $ (57,394) $ 66 $ 43,648
Six Months Ended June 30,
Common Stock Other
Paid-In
Capital Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury Stock Non-
controlling
Interests Total
($ and shares in millions except per share
amounts) Shares Par Value Shares Cost
Balance at January 1, 2023 3,577 $ 1,788 $ 44,379 $ 61,081 $ (4,768) 1,039 $ (56,489) $ 67 $ 46,058
Net loss attributable to Merck & Co., Inc. — — — (3,154) — — — — (3,154)
Other comprehensive loss, net of taxes — — — — (132) — — — (132)
Cash dividends declared on common stock
($1.46 per share) — — — (3,729) — — — — (3,729)
Treasury stock shares purchased — — — — — 4 (487) — (487)
Share-based compensation plans and other — — (160) — — (5) 364 — 204
Net income attributable to noncontrolling
interests — — — — — — — 7 7
Distributions attributable to noncontrolling
interests — — — — — — — (25) (25)
Balance at June 30, 2023 3,577 $ 1,788 $ 44,219 $ 54,198 $ (4,900) 1,038 $ (56,612) $ 49 $ 38,742
Balance at January 1, 2024 3,577 $ 1,788 $ 44,509 $ 53,895 $ (5,161) 1,045 $ (57,450) $ 54 $ 37,635
Net income attributable to Merck & Co., Inc. — — — 10,217 — — — — 10,217
Other comprehensive loss, net of taxes — — — — (200) — — — (200)
Cash dividends declared on common stock
($1.54 per share) — — — (3,925) — — — — (3,925)
Treasury stock shares purchased — — — — — 3 (373) — (373)
Share-based compensation plans and other — — (147) — — (7) 429 1 283
Net income attributable to noncontrolling
interests — — — — — — — 11 11
Balance at June 30, 2024 3,577 $ 1,788 $ 44,362 $ 60,187 $ (5,361) 1,041 $ (57,394) $ 66 $ 43,648
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 24 -

-- 24 of 51 --

10. Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its
international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:
Three Months Ended
June 30, Six Months Ended
June 30,
2024 2023 2024 2023
($ in millions) U.S. International U.S. International U.S. International U.S. International
Service cost $ 86 $ 60 $ 76 $ 50 $ 173 $ 122 $ 152 $ 99
Interest cost 134 73 133 75 269 147 266 149
Expected return on plan assets (207) (137) (185) (130) (417) (278) (372) (257)
Amortization of unrecognized
prior service (credit) cost — (3) — 16 — (6) (1) 12
Net loss (gain) amortization 10 1 — (1) 20 3 — (2)
Termination benefits — — 1 — 4 — 1 —
Curtailments — — 2 — — — 5 —
Settlements — — 5 — — — 26 —
$ 23 $ (6) $ 32 $ 10 $ 49 $ (12) $ 77 $ 1
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their
dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Service cost $ 8 $ 8 $ 15 $ 17
Interest cost 14 16 28 31
Expected return on plan assets (20) (16) (40) (32)
Amortization of unrecognized prior service credit (11) (12) (21) (25)
Net gain amortization (12) (11) (24) (21)
$ (21) $ (15) $ (42) $ (30)
In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to
expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were
recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered partial settlement
charges in the second quarter and first six months of 2023. These partial settlements triggered remeasurements of some of the
Company’s U.S. pension plans. Remeasurements during the first six months of 2023 resulted in a net increase of $47 million to
net pension liabilities and also resulted in a related adjustment to AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other
(income) expense, net (see Note 11), with the exception of certain amounts for termination benefits, curtailments and
settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or
settlement related to restructuring actions.
11. Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Interest income $ (69) $ (109) $ (141) $ (221)
Interest expense 310 277 613 519
Exchange losses 60 62 144 122
(Income) loss from investments in equity securities, net (1) (56) 175 (200) (274)
Net periodic defined benefit plan (credit) cost other than service cost (159) (111) (319) (226)
Other, net (44) (122) (85) 339
$ 42 $ 172 $ 12 $ 259
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment
funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from
ownership interests in investment funds are accounted for on a one quarter lag.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 25 -

-- 25 of 51 --

Other, net (as reflected in the table above) in the first six months of 2023 includes a $572.5 million charge related to
settlements with certain plaintiffs in the Zetia antitrust litigation.
Interest paid for the six months ended June 30, 2024 and 2023 was $581 million and $449 million, respectively.
12. Income Taxes
The effective income tax rates were 9.1% and 12.4% for the second quarter and first six months of 2024, respectively.
The effective income tax rates in the second quarter and first six months of 2024 reflect a 4.3 percentage point favorable impact
and a 2.2 percentage point favorable impact, respectively, due to a $259 million reduction in reserves for unrecognized income
tax benefits resulting from the expiration in June 2024 of the statute of limitations for assessments related to the 2019 federal tax
return year. The effective income tax rate for the first six months of 2024 also reflects a 0.7 percentage point unfavorable discrete
impact of a charge for the acquisition of Harpoon for which no tax benefit was recognized.
The income tax provision of $637 million and $1.5 billion for the second quarter and first six months of 2023,
respectively, on pretax losses of $5.3 billion and $1.7 billion, respectively, resulted in effective income tax rates of (11.9)% and
(86.8)%, respectively. The second quarter 2023 effective income tax rate includes the impact of a charge for the acquisition of
Prometheus for which no tax benefit was recognized, which unfavorably affected the tax rate by 25.1 percentage points, as well
as the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate. The
effective income tax rate for the first six months of 2023 includes a 101.9 percentage point combined unfavorable impact of
charges for the acquisitions of Prometheus and Imago for which no tax benefits were recognized, as well as higher foreign taxes,
the impact of the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017 (TCJA) on the Company’s U.S. global
intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the
U.S. tax rate, partially offset by higher foreign tax credits.
The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years
2017 and 2018, including the one-time transition tax enacted under the TCJA. If the IRS disagrees with the Company’s transition
tax position, it may result in a significant tax liability. The statute of limitations for assessments with respect to the 2019 federal
tax return year expired in June 2024 as noted above. The statute of limitations for assessments with respect to the 2020 federal
tax return year will expire in October of 2024, unless extended.
13. Earnings Per Share
The calculations of earnings (loss) per share are as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ and shares in millions except per share amounts) 2024 2023 2024 2023
Net Income (Loss) Attributable to Merck & Co., Inc. $ 5,455 $ (5,975) $ 10,217 $ (3,154)
Average common shares outstanding 2,534 2,539 2,534 2,539
Common shares issuable (1) 10 — 10 —
Average common shares outstanding assuming dilution 2,544 2,539 2,544 2,539
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc.
Common Shareholders $ 2.15 $ (2.35) $ 4.03 $ (1.24)
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck &
Co., Inc. Common Shareholders $ 2.14 $ (2.35) $ 4.02 $ (1.24)
(1) Issuable primarily under share-based compensation plans.
For the second quarter and first six months of 2024, 7 million and 5 million, respectively, of common shares issuable
under share-based compensation plans were excluded from the computations of earnings per common share assuming dilution
because the effect would have been antidilutive. The Company recorded a net loss for the three and six months ended June 30,
2023; therefore, no potential dilutive common shares were used in the computations of loss per common share assuming dilution
because the effects would have been antidilutive.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 26 -

-- 26 of 51 --

14. Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended June 30,
($ in millions) Derivatives
Employee
Benefit
Plans
Foreign
Currency
Translation
Adjustment
Accumulated
Other
Comprehensive
Loss
Balance April 1, 2023, net of taxes $ (60) $ (2,458) $ (2,365) $ (4,883)
Other comprehensive income (loss) before reclassification
adjustments, pretax 194 (6) (115) 73
Tax (41) 1 (22) (62)
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 153 (5) (137) 11
Reclassification adjustments, pretax (11) (1) (23) (2) — (34)
Tax 3 3 — 6
Reclassification adjustments, net of taxes (8) (20) — (28)
Other comprehensive income (loss), net of taxes 145 (25) (137) (17)
Balance June 30, 2023, net of taxes $ 85 $ (2,483) $ (2,502) $ (4,900)
Balance April 1, 2024, net of taxes $ 106 $ (2,798) $ (2,582) $ (5,274)
Other comprehensive income (loss) before reclassification
adjustments, pretax 139 1 (157) (17)
Tax (29) 2 (7) (34)
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 110 3 (164) (51)
Reclassification adjustments, pretax (55) (1) (15) (2) 20 (50)
Tax 12 2 — 14
Reclassification adjustments, net of taxes (43) (13) 20 (36)
Other comprehensive income (loss), net of taxes 67 (10) (144) (87)
Balance June 30, 2024, net of taxes $ 173 $ (2,808) $ (2,726) $ (5,361)
Six Months Ended June 30,
($ in millions) Derivatives
Employee
Benefit
Plans
Foreign
Currency
Translation
Adjustment
Accumulated
Other
Comprehensive
Loss
Balance January 1, 2023, net of taxes $ 73 $ (2,408) $ (2,433) $ (4,768)
Other comprehensive income (loss) before reclassification
adjustments, pretax 128 (53) (36) 39
Tax (27) 3 (42) (66)
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 101 (50) (78) (27)
Reclassification adjustments, pretax (113) (1) (30) (2) 9 (134)
Tax 24 5 — 29
Reclassification adjustments, net of taxes (89) (25) 9 (105)
Other comprehensive income (loss), net of taxes 12 (75) (69) (132)
Balance June 30, 2023, net of taxes $ 85 $ (2,483) $ (2,502) $ (4,900)
Balance January 1, 2024, net of taxes $ (24) $ (2,793) $ (2,344) $ (5,161)
Other comprehensive income (loss) before reclassification
adjustments, pretax 348 6 (382) (28)
Tax (73) (2) (20) (95)
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 275 4 (402) (123)
Reclassification adjustments, pretax (99) (1) (30) (2) 20 (109)
Tax 21 11 — 32
Reclassification adjustments, net of taxes (78) (19) 20 (77)
Other comprehensive income (loss), net of taxes 197 (15) (382) (200)
Balance June 30, 2024, net of taxes $ 173 $ (2,808) $ (2,726) $ (5,361)
(1) Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2) Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 27 -

-- 27 of 51 --

15. Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments,
Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health
pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human
disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals,
government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit
managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines.
The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A
large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention
Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal
government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary
pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and
control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally
connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors,
animal producers, farmers and pet owners.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 28 -

-- 28 of 51 --

Sales of the Company’s products were as follows:
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
($ in millions) U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total
Pharmaceutical:
Oncology
Keytruda $ 4,412 $ 2,858 $ 7,270 $ 3,863 $ 2,408 $ 6,271 $ 8,531 $ 5,686 $ 14,217 $ 7,348 $ 4,718 $ 12,065
Alliance revenue-Lynparza (1) 153 165 317 144 166 310 288 321 609 286 299 585
Alliance revenue-Lenvima (1) 177 73 249 163 79 242 349 155 504 316 158 474
Welireg 116 10 126 49 2 50 194 17 211 90 3 92
Alliance revenue-Reblozyl (2) 75 15 90 36 11 47 133 28 161 66 24 90
Vaccines
Gardasil/Gardasil 9 536 1,941 2,478 464 1,994 2,458 1,024 3,702 4,727 880 3,550 4,430
ProQuad/M-M-R II/Varivax 490 127 617 447 135 582 928 259 1,187 868 242 1,109
Vaxneuvance 99 90 189 147 20 168 260 148 408 241 33 274
RotaTeq 107 56 163 93 37 131 257 123 379 273 155 428
Pneumovax 23 11 48 59 23 69 92 17 103 120 63 125 188
Hospital Acute Care
Bridion 351 104 455 299 203 502 680 215 895 576 413 989
Prevymis 90 98 188 61 82 143 165 197 362 116 157 273
Dificid 79 12 92 68 8 76 147 17 165 130 11 141
Zerbaxa 33 28 62 30 24 54 67 51 118 57 47 104
Noxafil — 44 45 11 45 55 8 92 101 25 91 116
Cardiovascular
Alliance revenue-Adempas/
Verquvo (3) 98 8 106 70 (2) 68 188 16 203 153 14 167
Adempas — 72 72 — 65 65 — 142 142 — 125 125
Winrevair 70 — 70 — — — 70 — 70 — — —
Virology
Lagevrio 15 95 110 2 201 203 60 400 460 — 595 595
Isentress/Isentress HD 43 46 89 56 80 136 93 107 200 108 151 259
Delstrigo 14 45 60 13 37 50 26 89 116 24 70 94
Pifeltro 27 12 39 27 11 38 56 25 81 51 21 72
Neuroscience
Belsomra 19 34 53 21 42 63 33 66 99 37 82 119
Immunology
Simponi — 172 172 — 180 180 — 356 356 — 359 359
Remicade — 35 35 — 48 48 — 74 74 — 99 99
Diabetes
Januvia 177 227 405 243 267 511 361 463 824 514 548 1,062
Janumet 17 208 224 82 272 354 55 420 475 138 544 683
Other pharmaceutical (4) 190 386 573 158 403 560 346 807 1,151 328 857 1,187
Total Pharmaceutical segment
sales 7,399 7,009 14,408 6,570 6,887 13,457 14,336 14,079 28,415 12,688 13,491 26,179
Animal Health:
Livestock 168 669 837 165 643 807 334 1,352 1,686 338 1,318 1,656
Companion Animal 287 358 645 310 339 649 595 712 1,307 618 673 1,291
Total Animal Health segment
sales 455 1,027 1,482 475 982 1,456 929 2,064 2,993 956 1,991 2,947
Total segment sales 7,854 8,036 15,890 7,045 7,869 14,913 15,265 16,143 31,408 13,644 15,482 29,126
Other (5) 22 200 222 (27) 149 122 89 390 479 32 364 396
$ 7,876 $ 8,236 $ 16,112 $ 7,018 $ 8,018 $ 15,035 $ 15,354 $ 16,533 $ 31,887 $ 13,676 $ 15,846 $ 29,522
U.S. plus international may not equal total due to rounding.
(1) Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2) Alliance revenue for Reblozyl represents royalties (see Note 3).
(3) Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and
commercialization costs (see Note 3).
(4) Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5) Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $118 million and $128 million for the six months
ended June 30, 2024 and 2023, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the six months ended
June 30, 2024 and 2023 also includes $76 million and $54 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 29 -

-- 29 of 51 --

Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts
that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed
based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare
Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in
the aggregate, reduced U.S. sales by $3.3 billion and $3.2 billion for the three months ended June 30, 2024 and 2023,
respectively, and $6.6 billion and $6.3 billion for the six months ended June 30, 2024 and June 30, 2023, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
United States $ 7,876 $ 7,018 $ 15,354 $ 13,676
Europe, Middle East and Africa 3,515 3,348 7,078 6,651
China 1,817 1,913 3,589 3,628
Latin America 858 742 1,655 1,403
Japan 686 675 1,507 1,434
Asia Pacific (other than China and Japan) 748 848 1,472 1,694
Other 612 491 1,232 1,036
$ 16,112 $ 15,035 $ 31,887 $ 29,522
A reconciliation of segment profits to Income (Loss) Before Taxes is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Segment profits:
Pharmaceutical segment $ 11,200 $ 9,854 $ 22,104 $ 18,993
Animal Health segment 508 467 1,064 1,032
Total segment profits 11,708 10,321 23,168 20,025
Other profits 129 19 274 184
Unallocated:
Interest income 69 109 141 221
Interest expense (310) (277) (613) (519)
Amortization (614) (477) (1,087) (1,020)
Depreciation (450) (376) (902) (775)
Research and development (3,360) (13,194) (7,209) (17,341)
Restructuring costs (80) (151) (202) (218)
Charge for Zetia antitrust litigation settlements — — — (573)
Other unallocated, net (1,086) (1,309) (1,895) (1,669)
$ 6,006 $ (5,335) $ 11,675 $ (1,685)
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and
administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less
all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred
by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the
remaining cost of sales not included in segment profits as described above, research and development expenses incurred by
Merck Research Laboratories, the Company’s research and development division that focuses on human health-related
activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities.
Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets
utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring
activities, as well as the amortization of intangible assets and amortization of purchase accounting adjustments are not allocated
to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to
third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset
impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value
measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
- 30 -

-- 30 of 51 --

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Business Development Transactions
Below is a summary of significant business development activity thus far in 2024.
In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco) for approximately
$1.3 billion. The Elanco aqua business consists of an innovative portfolio of medicines and vaccines, nutritionals and
supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility
in Chile. The acquisition broadens Animal Health’s aqua portfolio with products such as Clynav, a new generation DNA-based
vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition
also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water
vaccine portfolio. In addition to these products, the DNA-based vaccine technology that is a part of the business has the potential
to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. The Company is in the
process of determining the preliminary fair value of assets acquired, liabilities assumed and total consideration transferred in this
transaction, which will be accounted for as a business combination.
Also in July 2024, Merck acquired Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused
biotechnology company for an upfront payment of $1.3 billion. The acquisition agreement also provides for a further $1.7 billion
in potential developmental, regulatory and sales-based milestone payments. EyeBio’s development work focused on candidates
for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases.
EyeBio’s lead candidate, Restoret/MK-3000 (formerly EYE103), is an investigational, potentially first-in-class tetravalent, tri-
specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, which is in clinical
development for the treatment of diabetic macular edema and neovascular age-related macular degeneration. The transaction
will be accounted for as an asset acquisition. Merck will record a charge of approximately $1.3 billion to Research and
development expenses, or approximately $0.51 per share, in the third quarter of 2024.
Additionally in July 2024, Merck and Orion Corporation (Orion) announced the mutual exercise of an option to convert
the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an
investigational cytochrome P450 11A1 (CYP11A1) inhibitor, and other candidates targeting CYP11A1, into an exclusive global
license for Merck. With the exercise of the option, Merck will assume full responsibility for all past and future development and
commercialization expenses associated with the candidates covered by the original agreement. In addition, Orion will become
eligible to receive developmental, regulatory and sales-based milestone payments, as well as annually tiered royalty payments
ranging from a low double-digit rate up to a rate in the low twenties on net sales for any commercialized licensed product. Orion
will retain responsibility for the manufacture of clinical and commercial supply for Merck. No payment was associated with the
exercise of the option. The exclusive global license is expected to become effective in the third quarter of 2024, but is subject to
certain conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions.
In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company
developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients
suffering from cancer and other diseases, for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead
candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch
ligand that is expressed at high levels in small-cell lung cancer (SCLC) and neuroendocrine tumors. MK-6070 is currently being
evaluated as monotherapy in a Phase 1/2 clinical trial in certain patients with advanced cancers associated with expression of
DLL3. The study is also evaluating MK-6070 in combination with atezolizumab in certain patients with SCLC. The transaction
was accounted for as an asset acquisition. Merck recorded net assets of $165 million, as well as a charge of $656 million, or
$0.26 per share, to Research and development expenses in the first six months of 2024 related to the transaction. There are no
future contingent payments associated with the acquisition.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access
worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased
purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to
pricing pressure. In 2021, the U.S. Congress passed the American Rescue Plan Act, which included a provision that eliminates
the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. Accordingly, manufacturers may
have to pay state Medicaid programs more in rebates than they receive on sales of particular products. As a result of this
provision, the Company has recognized increased discounts for Januvia (sitagliptin) and Janumet (sitagliptin and metformin HCl)
in the first six months of 2024. In 2022, the U.S. Congress passed the Inflation Reduction Act (IRA), which makes significant
changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for
drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to
bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in
2026) and Medicare Part B drugs (starting in 2028). In August 2023, the U.S. Department of Health and Human Services (HHS),
through the Centers for Medicare & Medicaid Services (CMS), announced that Januvia would be included in the first year of the
IRA’s “Drug Price Negotiation Program” (Program). Pursuant to the IRA’s Program, discussions with the government have now
concluded, with government price-setting becoming effective on January 1, 2026. The Company has sued the U.S. government
regarding the IRA’s Program. Furthermore, the Biden Administration and Congress continue to discuss legislation designed to
control health care costs, including the cost of drugs. In several international markets, government-mandated pricing actions
have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first six months of 2024
- 31 -

-- 31 of 51 --

was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care
costs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.
Operating Results
Sales
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
United States $ 7,876 $ 7,018 12 % 12 % $ 15,354 $ 13,676 12 % 12 %
International 8,236 8,018 3 % 9 % 16,533 15,846 4 % 11 %
Total $ 16,112 $ 15,035 7 % 11 % $ 31,887 $ 29,522 8 % 11 %
U.S. plus international may not equal total due to rounding.
Worldwide sales were $16.1 billion in the second quarter of 2024, representing growth of 7% compared with the
second quarter of 2023, or 11% excluding the unfavorable effect of foreign exchange. Global sales were $31.9 billion in the first
six months of 2024, an increase of 8% compared with the same period of 2023, or 11% excluding the unfavorable effect of
foreign exchange. Approximately 2 percentage points of the negative impact of foreign exchange in both periods was due to the
devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that
market. Global sales growth in both periods was primarily due to higher sales in the oncology franchise, largely due to strong
growth of Keytruda (pembrolizumab) and Welireg (belzutifan). Higher sales in the vaccines franchise also contributed to revenue
growth in the second quarter and first six months of 2024, reflecting increased combined sales of Gardasil (Human
Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/Gardasil 9 (Human Papillomavirus 9-valent
Vaccine, Recombinant) and continued uptake of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for pediatric use.
Revenue growth in the second quarter and first six months of 2024 also benefited from higher sales in the cardiovascular
franchise largely attributable to the launch of Winrevair (sotatercept-csrk). Revenue growth in the second quarter and first six
months of 2024 was partially offset by lower sales in the diabetes franchise attributable to Januvia and Janumet, as well as lower
sales in the virology franchise largely due to Lagevrio (molnupiravir).
See Note 15 to the condensed consolidated financial statements for details on sales of the Company’s products. A
discussion of performance for select products in the franchises follows. All product or service marks appearing in type form
different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck,
its subsidiaries or affiliates, except as noted. All other trademarks or services marks are those of their respective owners.
Pharmaceutical Segment
Oncology
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Keytruda $ 7,270 $ 6,271 16 % 21 % $ 14,217 $ 12,065 18 % 22 %
Alliance Revenue - Lynparza (1) 317 310 2 % 4 % 609 585 4 % 6 %
Alliance Revenue - Lenvima (1) 249 242 3 % 4 % 504 474 6 % 7 %
Welireg 126 50 * * 211 92 * *
Alliance Revenue - Reblozyl (2) 90 47 92 % 92 % 161 90 80 % 80 %
* > 100%
(1) Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see
Note 3 to the condensed consolidated financial statements).
(2) Alliance revenue for Reblozyl represents royalties (see Note 3 to the condensed consolidated financial statements).
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved in 40 indications in the
U.S., including 17 tumor types and 2 tumor-agnostic indications, and has similarly been approved in markets worldwide for many
of these indications. The Keytruda clinical development program includes studies across a broad range of cancer types. See
“Research and Development Update” below.
Global sales of Keytruda grew 16% in the second quarter of 2024 and rose 18% in the first six months of 2024, or
21% and 22%, respectively, excluding the unfavorable effect of foreign exchange. Approximately 4 percentage points of the
negative impact of foreign exchange in both periods was due to the devaluation of the Argentine peso, which was largely offset
by inflation-related price increases consistent with practice in that market. Keytruda sales growth in the U.S. reflects increased
uptake across earlier-stage indications, including in certain types of non-small-cell lung cancer (NSCLC), high-risk early-stage
triple-negative breast cancer (TNBC), and certain types of renal cell carcinoma (RCC), as well as higher demand across the
multiple approved metastatic indications, in particular for the treatment of certain types of urothelial, endometrial, microsatellite
instability-high (MSI-H) and renal cell cancers, as well as higher pricing. Keytruda sales growth in international markets reflects
higher demand predominately for the TNBC, melanoma and RCC earlier-stage indications, as well as uptake in cervical, renal
and gastric cancer metastatic indications, particularly in Europe and Latin America.
- 32 -

-- 32 of 51 --

Keytruda has received the following regulatory approvals thus far in 2024.
Date Approval
January
2024
U.S. Food and Drug Administration (FDA) approval in combination with chemoradiotherapy for the treatment of
patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer,
based on the KEYNOTE-A18 trial.
January
2024
FDA full approval for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who
have received prior systemic therapy other than a PD-1/PD-L1 containing regimen. The conversion from an
accelerated to full (regular) approval is based on the KEYNOTE-394 trial.
February
2024
China’s National Medical Products Administration (NMPA) approval in combination with gemcitabine and cisplatin for
the first-line treatment of patients with locally advanced or metastatic biliary tract carcinoma, based on the
KEYNOTE-966 trial.
March
2024
European Commission (EC) approval in combination with platinum-containing chemotherapy as neoadjuvant
treatment, then continued as monotherapy as adjuvant treatment, for resectable NSCLC at high risk of recurrence in
adults, based on the KEYNOTE-671 trial.
May 2024 Japan’s Ministry of Health, Labor and Welfare (MHLW) approval in combination with fluoropyrimidine- and platinum-
containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic
gastric or gastroesophageal junction (GEJ) adenocarcinoma, based on the KEYNOTE-859 trial.
May 2024 Japan’s MHLW approval in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the
treatment of patients with locally advanced unresectable or metastatic biliary tract cancer, based on the
KEYNOTE-966 trial.
June
2024
FDA approval in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the
treatment of adult patients with primary advanced or recurrent endometrial carcinoma, based on the NRG-GY018
trial, also known as KEYNOTE-868.
June
2024
China’s NMPA approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy
for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth
factor receptor 2 (HER2) positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 as determined by a
fully validated test, based on the KEYNOTE-811 trial.
The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on
sales of Keytruda. Under the terms of the more significant of these agreements, Merck paid a royalty of 6.5% on worldwide sales
of Keytruda through December 2023 to one third party; this royalty declined to 2.5% in 2024 and will continue through 2026,
terminating thereafter. The Company pays an additional 2% royalty on worldwide sales of Keytruda to another third party, the
termination date of which varies by country; this royalty will expire in the U.S. in September 2024 and on varying dates in major
European markets in the second half of 2025. The royalty expenses are included in Cost of sales.
Lynparza (olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a
collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements). Lynparza is
approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic
and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza increased 2% in the second quarter of
2024 primarily driven by higher demand in the U.S. and certain international markets, particularly in China and Europe. Alliance
revenue related to Lynparza grew 4% in the first six months of 2024 primarily due to higher demand in certain international
markets, particularly in Latin America, China and Europe.
Lenvima (lenvatinib) is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai
Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements). Lenvima is approved for the treatment of
certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in
combination with Keytruda for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related
to Lenvima grew 3% and 6% in the second quarter and first six months of 2024, respectively, primarily reflecting higher demand
in the U.S.
Sales of Welireg, for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors
and certain adult patients with previously treated advanced RCC, more than doubled in both the second quarter and first six
months of 2024. Sales growth in both periods was primarily due to higher demand in the U.S. largely attributable to the launch of
a new indication for previously treated advanced RCC following approval by the FDA in December 2023. Welireg is under review
in the European Union (EU) and Japan for the treatment of previously treated advanced RCC based on the LITESPARK-005
clinical trial and in the EU for the treatment of VHL disease based on the LITESPARK-004 clinical trial.
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being
commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS) (see Note 3 to the condensed
consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Alliance
revenue related to this collaboration (consisting of royalties) increased 92% and 80% in the second quarter and first six months
of 2024, respectively, due to strong underlying sales performance.
- 33 -

-- 33 of 51 --

Vaccines
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Gardasil/Gardasil 9 $ 2,478 $ 2,458 1 % 4 % $ 4,727 $ 4,430 7 % 10 %
ProQuad 239 222 7 % 8 % 443 412 8 % 8 %
M-M-R II 113 104 8 % 9 % 217 207 5 % 6 %
Varivax 266 255 4 % 5 % 527 491 7 % 8 %
Vaxneuvance 189 168 13 % 16 % 408 274 49 % 51 %
RotaTeq 163 131 25 % 26 % 379 428 (11) % (10) %
Pneumovax 23 59 92 (36) % (32) % 120 188 (36) % (32) %
Combined worldwide sales of Gardasil and Gardasil 9, vaccines to help prevent certain cancers and other diseases
caused by certain types of human papillomavirus (HPV), grew 1% in the second quarter of 2024 primarily driven by higher
sales in the U.S. due to higher pricing, demand and public sector buying patterns, as well as higher demand in several ex-U.S.
markets. Sales growth of Gardasil/Gardasil 9 in the second quarter of 2024 was largely offset by lower sales in China due to
the timing of shipments compared with prior year. Combined worldwide sales of Gardasil and Gardasil 9 grew 7% in the first
six months of 2024 primarily due to higher global demand, as well as public sector buying patterns in the U.S., and higher
pricing. In the second quarter of 2024, the Company observed a significant decline in shipments from its distributor and
commercialization partner in China, Zhifei Biological Products Co., Ltd. (Zhifei), into the points of vaccination compared with
prior quarters, resulting in above normal inventory levels at Zhifei. If shipments from Zhifei into the points of vaccination do not
increase, it is likely that the Company will ship less than its full year 2024 contracted doses by the end of 2024.
The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on
sales of Gardasil/Gardasil 9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on sales of
Gardasil/Gardasil 9 in the U.S. to one third party (this royalty expires in December 2028); Merck paid an additional 7% royalty on
worldwide sales of Gardasil/Gardasil 9 to another third party, which expired in December 2023. The royalty expenses are
included in Cost of sales.
Global sales of ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination
vaccine to help protect against measles, mumps, rubella and varicella, grew 7% and 8% in the second quarter and first six
months of 2024, respectively, primarily reflecting higher pricing and demand in the U.S.
Worldwide sales of M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles,
mumps and rubella, grew 8% and 5% in the second quarter and first six months of 2024, respectively, largely reflecting higher
demand in several ex-U.S. markets.
Global sales of Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), increased 4%
and 7% in the second quarter and first six months of 2024, respectively, primarily attributable to higher pricing in the U.S. Sales
growth in the second quarter of 2024 was partially offset by the timing of sales in Latin America.
Worldwide sales of Vaxneuvance, a vaccine to help protect against invasive pneumococcal disease, grew 13% in the
second quarter of 2024 primarily reflecting continued uptake following launches in the pediatric indication in Japan and Europe,
partially offset by lower sales in the U.S. due to lower demand and public sector buying patterns. Worldwide sales of
Vaxneuvance grew 49% in the first six months of 2024 primarily reflecting higher demand in Europe and Japan, as well as the
beneficial impact of public sector buying patterns in the U.S.
Global sales of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus
gastroenteritis in infants and children, grew 25% in the second quarter of 2024 largely due to the timing of sales in China, as well
as higher sales in the U.S. reflecting a benefit from public sector buying patterns that was partially offset by lower demand.
Worldwide sales of RotaTeq declined 11% first six months of 2024 primarily due to lower sales in China reflecting first quarter
2023 inventory stocking, as well as lower sales in the U.S. due to lower demand and public sector buying patterns, partially offset
by higher pricing.
Worldwide sales of Pneumovax 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal
disease, declined 36% in both the second quarter and first six months of 2024 driven by lower demand in most markets,
particularly in the U.S. as the market has shifted toward newer adult pneumococcal conjugate vaccines.
In June 2024, the FDA approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for the prevention of
invasive pneumococcal disease and pneumococcal pneumonia in individuals 18 years of age and older. The approval was
supported by results from multiple Phase 3 clinical studies evaluating Capvaxive in both vaccine-naïve and vaccine-experienced
adult patient populations, including STRIDE-3, STRIDE-4, STRIDE-5 and STRIDE-6. In June 2024, the U.S. Centers for Disease
Control and Prevention’s (CDC) Advisory Committee on Immunization Practices unanimously voted to recommend Capvaxive as
an option for certain adults for pneumococcal vaccination. These provisional recommendations were adopted by the CDC
director and are now official. Merck is a party to certain third-party license agreements pursuant to which the Company will pay
royalties on sales of Capvaxive. Under the more significant of these agreements, Merck will pay a royalty of 7.25% on net sales
of Capvaxive through 2026; this royalty will decline to 2.5% on net sales from 2027 through 2035.
- 34 -

-- 34 of 51 --

Hospital Acute Care
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Bridion $ 455 $ 502 (9) % (8) % $ 895 $ 989 (9) % (8) %
Prevymis 188 143 31 % 35 % 362 273 33 % 37 %
Worldwide sales of Bridion (sugammadex), for the reversal of two types of neuromuscular blocking agents used
during surgery, declined 9% in both the second quarter and first six months of 2024 primarily driven by lower demand in certain
ex-U.S. markets due to generic competition, particularly in the EU and the Asia Pacific region, partially offset by higher demand
in the U.S. The patent that provided market exclusivity for Bridion in the EU expired in July 2023. Accordingly, the Company is
experiencing sales declines of Bridion in these markets and expects the declines to continue. The patent that provided market
exclusivity for Bridion in Japan expired in January 2024; the Company anticipates sales of Bridion in Japan will decline in future
periods.
Worldwide sales of Prevymis (letermovir), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection
and disease in certain high risk adult recipients of an allogenic hematopoietic stem cell transplant and for prophylaxis of CMV
disease in certain high risk adult recipients of a kidney transplant, grew 31% and 33% in the second quarter and first six months
of 2024, respectively, largely due to higher global demand, particularly in the U.S., China and Europe.
Cardiovascular
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Alliance Revenue - Adempas/
Verquvo (1) $ 106 $ 68 56 % 56 % $ 203 $ 167 22 % 22 %
Adempas 72 65 11 % 15 % 142 125 14 % 17 %
Winrevair 70 — — — 70 — — —
(1) Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization
costs (see Note 3 to the condensed consolidated financial statements).
Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market
and develop soluble guanylate cyclase (sGC) modulators (see Note 3 to the condensed consolidated financial statements).
Adempas is approved for the treatment of certain types of pulmonary arterial hypertension (PAH) and chronic pulmonary
hypertension (PH). Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a
hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and
reduced ejection fraction. Alliance revenue from the collaboration grew 56% and 22% in the second quarter and first six months
of 2024, respectively, due to higher demand in Bayer’s marketing territories. Revenue also includes sales of Adempas and
Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories grew 11% and 14% in the second
quarter and first six months of 2024, respectively, primarily due to higher demand.
In March 2024, the FDA approved Winrevair for the treatment of adults with PAH (World Health Organization [WHO]
Group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The
approval is based on the STELLAR trial. Additional worldwide regulatory filings for Winrevair are underway. Winrevair is the
subject of a licensing agreement with BMS pursuant to which Merck pays a 22% royalty on sales of Winrevair to BMS. Merck
estimates approximately 40% of Winrevair sales in the second quarter 2024 were attributable to doses administered to patients,
with the remainder due to distributors building inventory in support of increasing demand.
Virology
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Lagevrio $ 110 $ 203 (46) % (42) % $ 460 $ 595 (23) % (18) %
Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback
Biotherapeutics LP (Ridgeback) (see Note 3 to the condensed consolidated financial statements). Sales of Lagevrio declined
46% and 23% in the second quarter and first six months of 2024, respectively, primarily due to lower demand and pricing in
certain markets in the Asia Pacific region, partially offset by uptake from commercial distribution in the U.S. and higher demand in
Japan.
- 35 -

-- 35 of 51 --

Immunology
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Simponi $ 172 $ 180 (4) % (2) % $ 356 $ 359 (1) % (1) %
Remicade 35 48 (27) % (20) % 74 99 (25) % (21) %
Simponi (golimumab) and Remicade (infliximab) are treatments for certain inflammatory diseases that the Company
markets in Europe, Russia and Türkiye. The Company’s marketing rights with respect to these products will revert to Johnson &
Johnson Innovative Medicine on October 1, 2024.
Diabetes
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Januvia/Janumet $ 629 $ 864 (27) % (23) % $ 1,299 $ 1,744 (26) % (22) %
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2
diabetes, declined 27% and 26% in the second quarter and first six months of 2024, respectively, primarily due to lower sales in
the U.S., largely reflecting lower pricing and lower demand due to competitive pressures, as well as the ongoing impact of the
loss of exclusivity in most markets in Europe and the Asia Pacific region, as well as in Canada.
The American Rescue Plan Act enacted in the U.S. in 2021 included a provision that eliminated the statutory cap on
rebates drug manufacturers pay to Medicaid beginning in January 2024. Accordingly, manufacturers may have to pay state
Medicaid programs more in rebates than they receive on sales of particular products. As a result of this provision, the Company
has recognized increased discounts for Januvia and Janumet in the first six months of 2024. In August 2023, the U.S.
Department of HHS, through the CMS, announced that Januvia would be included in the first year of the IRA’s Program.
Pursuant to the IRA’s Program, discussions with the government have now concluded, with government price-setting becoming
effective on January 1, 2026. The Company has sued the U.S. government regarding the IRA’s Program.
While the key U.S. patent for Januvia and Janumet claiming the sitagliptin compound expired in January 2023, as a
result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt
form of the products (see Note 8 to the condensed consolidated financial statements), the Company expects that Januvia and
Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S.
until July 2026, although a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin
products has been approved by the FDA. The Company anticipates pricing and volume declines for Januvia and Janumet in the
U.S. for the remainder of 2024.
The Company lost market exclusivity for Januvia in all of the EU and for Janumet in some European countries in
September 2022. Exclusivity for Janumet was lost in other European countries in April 2023. Accordingly, the Company is
experiencing sales declines in these markets and expects the declines to continue. Generic equivalents of Januvia and Janumet
have also launched in China.
Animal Health Segment
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 2024 2023 % Change 2024 2023 % Change
Livestock $ 837 $ 807 4 % 11 % $ 1,686 $ 1,656 2 % 7 %
Companion Animal 645 649 (1) % 1 % 1,307 1,291 1 % 3 %
$ 1,482 $ 1,456 2 % 6 % $ 2,993 $ 2,947 2 % 5 %
Animal Health sales grew 2% in the second quarter of 2024, or 6% excluding the unfavorable effect of foreign
exchange, and increased 2% in the first six months of 2024, or 5% excluding the unfavorable effect of foreign exchange.
Approximately 3 percentage points of the negative impact of foreign exchange in both periods was due to the devaluation of the
Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market.
Sales of livestock products grew 4% and 2% in the second quarter and first six months of 2024, respectively, primarily
due to higher pricing, as well as increased demand for poultry products. Higher demand for ruminant products also contributed to
sales growth in the second quarter of 2024. Sales of companion animal products were relatively flat in the second quarter of
2024. Sales of companion animal products grew 1% in the first six months of 2024 due to higher pricing, largely offset by lower
volumes reflecting a reduction in distributor inventory. Sales of Bravecto (fluralaner), a line of oral, topical and injectable parasitic
control products, were $331 million for the second quarter of 2024, representing growth of 2% compared with the second quarter
of 2023, or 3% excluding the unfavorable effect of foreign exchange. Sales of Bravecto were $663 million for the first six months
of 2024, representing growth of 4% compared with the corresponding prior year period, or 5% excluding the unfavorable effect of
foreign exchange.
- 36 -

-- 36 of 51 --

In July 2024, Merck acquired the aqua business of Elanco for $1.3 billion. See “Business Development Transactions”
above for additional information related to this transaction.
Costs, Expenses and Other
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 % Change 2024 2023 % Change
Cost of sales $ 3,745 $ 4,024 (7) % $ 7,285 $ 7,951 (8) %
Selling, general and administrative 2,739 2,702 1 % 5,221 5,182 1 %
Research and development 3,500 13,321 (74) % 7,492 17,597 (57) %
Restructuring costs 80 151 (47) % 202 218 (7) %
Other (income) expense, net 42 172 (76) % 12 259 (95) %
$ 10,106 $ 20,370 (50) % $ 20,212 $ 31,207 (35) %
Cost of Sales
Cost of sales declined 7% and 8% in the second quarter and first six months of 2024, respectively. Cost of sales
includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing
arrangements, which totaled $603 million and $468 million in the second quarter of 2024 and 2023, respectively, and $1.1 billion
and $1.0 billion in the first six months of 2024 and 2023, respectively. Amortization expense in the first six months of 2023
includes $72 million of cumulative catch-up amortization related to Merck’s collaboration with Eisai. See Note 3 to the condensed
consolidated financial statements for more information on Merck’s collaborative arrangements. Also included in Cost of sales are
expenses associated with restructuring activities, which amounted to $66 million and $32 million in the second quarter of 2024
and 2023, respectively, and $182 million and $61 million in the first six months of 2024 and 2023, respectively, primarily reflecting
accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs
associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as
discussed below.
Gross margin was 76.8% in the second quarter of 2024 compared with 73.2% in the second quarter of 2023. Gross
margin was 77.2% in the first six months of 2024 compared with 73.1% in the first six months of 2023. The gross margin
improvement in both periods was primarily due to the favorable effect of product mix (including lower royalty rates related to
Keytruda and Gardasil/Gardasil 9 sales), partially offset by higher restructuring costs and amortization of intangible assets.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses increased 1% in the second quarter of 2024 primarily due to
higher administrative and promotional costs, largely offset by the favorable effect of foreign exchange and lower restructuring
costs. SG&A expenses rose 1% in the first six months of 2024 primarily due to higher administrative costs, largely offset by the
favorable effect of foreign exchange, lower promotional spending, reflecting the prioritization of spending on key growth products,
as well as lower restructuring costs.
Research and Development
Research and development (R&D) expenses were $3.5 billion in the second quarter of 2024 compared with $13.3
billion in the second quarter of 2023. The decline was primarily due to a $10.2 billion charge in the second quarter of 2023 for the
acquisition of Prometheus. R&D expenses were $7.5 billion in the first six months 2024 compared with $17.6 billion in the first six
months of 2023. The decline was primarily due to lower charges for business development transactions, which included a $656
million charge for the acquisition of Harpoon in the first six months of 2024, compared with charges of $10.2 billion for the
acquisition of Prometheus, $1.2 billion for the acquisition of Imago and $175 million for a license and collaboration agreement
with Kelun-Biotech in the first six months of 2023. The declines in R&D expenses for both the second quarter and first six months
of 2024 were partially offset by increased clinical development spending, as well as higher compensation and benefit costs in
2024.
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s
research and development division that focuses on human health-related activities, which were $2.5 billion and $2.3 billion for
the second quarter of 2024 and 2023, respectively, and $4.9 billion and $4.3 billion for the first six months of 2024 and 2023,
respectively. Also included in R&D expenses are Animal Health research costs, upfront payments for collaboration and licensing
agreements, charges for transactions accounted for as asset acquisitions (including the charges for the Harpoon, Prometheus
and Imago acquisitions as noted above), and costs incurred by other divisions in support of R&D activities, including
depreciation, production and general and administrative, which in the aggregate were approximately $955 million and $11.1
billion for the second quarter of 2024 and 2023, respectively, and $2.5 billion and $13.3 billion for the first six months of 2024 and
2023, respectively.
Restructuring Costs
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to
continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new
- 37 -

-- 37 of 51 --

modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency.
The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031,
with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0
billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of
facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down
costs. The Company expects to record charges of approximately $800 million in 2024 related to the 2024 Restructuring Program.
The Company anticipates the actions under the 2024 Restructuring Program will result in cumulative annual net cost savings of
approximately $750 million by the end of 2031.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide
initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate
footprint. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January
1, 2024, any remaining activities are now being accounted for as part of the 2024 Restructuring Program.
Restructuring costs, primarily representing separation and other costs associated with these restructuring activities,
were $80 million and $151 million for the second quarter of 2024 and 2023, respectively, and $202 million and $218 million for
the first six months of 2024 and 2023, respectively. Separation costs incurred were associated with actual headcount reductions,
as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and
could be reasonably estimated. Other expenses in Restructuring costs include facility shut-down and other related costs, as well
as employee-related costs such as curtailment, settlement and termination charges associated with pension and other
postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are
unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general
and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of $177
million and $236 million in the second quarter of 2024 and 2023, respectively, and $422 million and $333 million for the first six
months of 2024 and 2023, respectively, related to restructuring program activities (see Note 4 to the condensed consolidated
financial statements).
Other (Income) Expense, Net
Other (income) expense, net was $42 million of expense in the second quarter of 2024 compared with $172 million of
expense in the second quarter of 2023 primarily due to net income from investments in equity securities in 2024 compared with
net losses in 2023, partially offset by higher net interest expense in 2024. Other (income) expense, net was $12 million of
expense in the first six months of 2024 compared with $259 million of expense in the first six months of 2023. The favorability
was primarily due to a $572.5 million charge in 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation,
partially offset by higher net interest expense and lower income from investments in equity securities in 2024.
For details on the components of Other (income) expense, net see Note 11 to the condensed consolidated financial
statements.
Segment Profits
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions) 2024 2023 2024 2023
Pharmaceutical segment profits $ 11,200 $ 9,854 $ 22,104 $ 18,993
Animal Health segment profits 508 467 1,064 1,032
Other (5,702) (15,656) (11,493) (21,710)
Income (Loss) Before Taxes $ 6,006 $ (5,335) $ 11,675 $ (1,685)
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses
directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as
SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating
decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D
expenses incurred by MRL, or general and administrative expenses not directly incurred by the segments, nor the cost of
financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including
depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also
excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-
related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible
asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for
contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost
centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also
included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party
manufacturing arrangements.
Pharmaceutical segment profits grew 14% and 16% in the second quarter and first six months of 2024, respectively,
primarily due to higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of
- 38 -

-- 38 of 51 --

foreign exchange. Animal Health segment profits rose 9% and 3% in the second quarter and first six months of 2024,
respectively, primarily due to higher sales, partially offset by increased promotional costs, as well as the unfavorable effect of
foreign exchange.
Taxes on Income
The effective income tax rates were 9.1% and 12.4% for the second quarter and first six months of 2024, respectively.
The effective income tax rates in the second quarter and first six months of 2024 reflect a 4.3 percentage point favorable impact
and a 2.2 percentage point favorable impact, respectively, due to a $259 million reduction in reserves for unrecognized income
tax benefits resulting from the expiration in June 2024 of the statute of limitations for assessments related to the 2019 federal tax
return year. The effective income tax rate for the first six months of 2024 also reflects a 0.7 percentage point unfavorable discrete
impact of a charge for the acquisition of Harpoon for which no tax benefit was recognized.
The income tax provision of $637 million and $1.5 billion for the second quarter and first six months of 2023,
respectively, on pretax losses of $5.3 billion and $1.7 billion, respectively, resulted in effective income tax rates of (11.9)% and
(86.8)%, respectively. The second quarter 2023 effective income tax rate includes the impact of a charge for the acquisition of
Prometheus for which no tax benefit was recognized, which unfavorably affected the tax rate by 25.1 percentage points, as well
as the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate. The
effective income tax rate for the first six months of 2023 includes a 101.9 percentage point combined unfavorable impact of
charges for the acquisitions of Prometheus and Imago for which no tax benefits were recognized, as well as higher foreign taxes,
the impact of the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017 (TCJA) on the Company’s U.S. global
intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the
U.S. tax rate, partially offset by higher foreign tax credits.
While many jurisdictions in which Merck operates have adopted the global minimum tax provision of the Organisation
for Economic Co-operation and Development (OECD) Pillar 2, effective for tax years beginning in January 2024, the Company
anticipates there will be a reduced impact to its 2024 tax rate due to the accounting for the tax effects of intercompany
transactions. The Company expects the impact of the global minimum tax will increase its tax rate to a greater extent in 2025 and
thereafter. Also, in the event that the provision of the TCJA requiring capitalization and amortization of R&D expenses for tax
purposes is repealed along the lines proposed in the Tax Relief for American Families and Workers Act of 2024, the Company
will again be able to realize the benefit of U.S. R&D expenses as incurred but expects no material impact to its effective income
tax rate.
Non-GAAP Income (Loss) and Non-GAAP EPS
Non-GAAP income (loss) and non-GAAP earnings (loss) per share (EPS) are alternative views of the Company’s
performance that Merck is providing because management believes this information enhances investors’ understanding of the
Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income (loss) and non-
GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of
underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of
acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and
certain other items. These excluded items are significant components in understanding and assessing financial performance.
Non-GAAP income (loss) and non-GAAP EPS are important internal measures for the Company. Senior management
receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures
internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In
addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP
pretax income (loss) metric. Since non-GAAP income (loss) and non-GAAP EPS are not measures determined in accordance
with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of
similar measures of other companies. The information on non-GAAP income (loss) and non-GAAP EPS should be considered in
addition to, but not as a substitute for or superior to, net income (loss) and EPS prepared in accordance with generally accepted
accounting principles in the U.S. (GAAP).
- 39 -

-- 39 of 51 --

A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
Three Months Ended
June 30, Six Months Ended
June 30,
($ in millions except per share amounts) 2024 2023 2024 2023
Income (loss) before taxes as reported under GAAP $ 6,006 $ (5,335) $ 11,675 $ (1,685)
Increase (decrease) for excluded items:
Acquisition- and divestiture-related costs 633 498 1,129 1,088
Restructuring costs 177 236 422 333
(Income) loss from investments in equity securities, net (49) 194 (165) (235)
Other items:
Charge for Zetia antitrust litigation settlements — — — 573
Non-GAAP income (loss) before taxes 6,767 (4,407) 13,061 74
Income tax provision as reported under GAAP 545 637 1,447 1,462
Estimated tax benefit on excluded items (1) 148 173 257 261
Tax benefit resulting from the expiration of the statute of limitations for assessments
related to the 2019 federal tax return year 259 — 259 —
Non-GAAP income tax provision 952 810 1,963 1,723
Non-GAAP net income (loss) 5,815 (5,217) 11,098 (1,649)
Less: Net income attributable to noncontrolling interests as reported under GAAP 6 3 11 7
Non-GAAP net income (loss) attributable to Merck & Co., Inc. $ 5,809 $ (5,220) $ 11,087 $ (1,656)
EPS assuming dilution as reported under GAAP (2)(3) $ 2.14 $ (2.35) $ 4.02 $ (1.24)
EPS difference 0.14 0.29 0.34 0.59
Non-GAAP EPS assuming dilution (2)(3) $ 2.28 $ (2.06) $ 4.36 $ (0.65)
(1) The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
(2) The Company recorded a net loss on both a GAAP and non-GAAP basis for the second quarter and first six months of 2023; therefore, no potential dilutive
common shares were used in the computations of loss per common share assuming dilution because the effects would have been antidilutive.
(3) GAAP and non-GAAP EPS were negatively affected in the second quarter of 2023 by $4.02 per share, and for the first six months of 2024 and 2023 by $0.26 per
share and $4.53 per share, respectively, of charges for certain upfront payments related to collaborations and licensing agreements, as well as charges related to
pre-approval assets obtained in transactions accounted for as asset acquisitions.
Acquisition- and Divestiture-Related Costs
Non-GAAP income (loss) and non-GAAP EPS exclude the impact of certain amounts recorded in connection with
acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets, as well as intangible
asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for
contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and
divestitures. Non-GAAP income (loss) and non-GAAP EPS also exclude amortization of intangible assets related to
collaborations and licensing arrangements.
Restructuring Costs
Non-GAAP income (loss) and non-GAAP EPS exclude costs related to restructuring actions (see Note 4 to the
condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation
associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the
depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be
closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the
restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as
employee-related costs such as curtailment, settlement and termination charges associated with pension and other
postretirement benefit plans and share-based compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income (loss) and non-GAAP EPS exclude realized and unrealized gains and losses from investments in
equity securities either owned directly or through ownership interests in investment funds.
Certain Other Items
Non-GAAP income (loss) and non-GAAP EPS exclude certain other items. These items are adjusted for after
evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that
are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from
non-GAAP income and non-GAAP EPS in 2024 is a benefit due to a reduction in reserves for unrecognized income tax benefits
resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year (see Note 12
to the condensed consolidated financial statements). Excluded from non-GAAP income (loss) and non-GAAP EPS in 2023 is a
charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
- 40 -

-- 40 of 51 --

Research and Development Update
The Company currently has several candidates under regulatory review in the U.S. and internationally.
MK-1022, patritumab deruxtecan, is a potential first-in-class HER3 directed DXd antibody drug conjugate (ADC),
under review by the FDA for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC
previously treated with two or more systemic therapies. The Biologics License Application (BLA) is based on the primary results
from the HERTHENA-Lung01 pivotal Phase 2 trial and data results presented at the IASLC 2023 World Conference on Lung
Cancer, which were simultaneously published in the Journal of Clinical Oncology. In June 2024, the FDA issued a complete
response letter (CRL) for the BLA due to findings pertaining to an inspection of a third-party manufacturing facility. The CRL did
not identify any issues with the efficacy or safety data submitted. Patritumab deruxtecan (HER3-DXd) was discovered by Daiichi
Sankyo and is being jointly developed by Daiichi Sankyo and Merck. Merck is working with Daiichi Sankyo to address FDA
feedback.
V116, Capvaxive, the Company’s 21-valent pneumococcal conjugate vaccine designed to help prevent invasive
pneumococcal disease and pneumococcal pneumonia in adults, is under review in the EU. The application is supported by
results from multiple Phase 3 clinical studies evaluating V116 in both vaccine-naïve and vaccine-experienced adult patient
populations, including STRIDE-3, STRIDE-4, STRIDE-5 and STRIDE-6.
MK-7962, Winrevair (sotatercept), Merck’s novel activin signaling inhibitor, is under review in the EU for the treatment
of adult patients with PAH. In June 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) recommended the approval of Winrevair, in combination with other PAH therapies, for the treatment of
PAH in adult patients with WHO functional class II to III, to improve exercise capacity. The CHMP recommendation is based on
data from the Phase 3 STELLAR trial. Winrevair was previously granted Priority Medicines (PRIME) scheme and Orphan Drug
designation by the EMA for the treatment of PAH. The EC will now review the CHMP recommendation, and the EC’s decision is
expected in the third quarter of 2024.
MK-7264, gefapixant, is a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of refractory or
unexplained chronic cough in adults. In December 2023, the FDA issued a second CRL regarding the resubmission of Merck’s
New Drug Application for gefapixant. In the CRL, the FDA concluded that Merck’s application did not meet substantial evidence
of effectiveness for treating refractory chronic cough and unexplained chronic cough. The CRL was not related to the safety of
gefapixant. Merck is reviewing the FDA’s feedback to determine next steps.
MK-3475, Keytruda, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical
development for expanded indications. These studies encompass more than 30 cancer types including: biliary, estrogen receptor
positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and
neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma,
mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical
development. Further trials are being planned for other cancers.
Keytruda is under priority review by the FDA in combination with chemotherapy, for the first-line treatment of adult
patients with unresectable advanced or metastatic malignant pleural mesothelioma, based on the Phase 2/3 IND.227/
KEYNOTE-483 trial. The FDA set a Prescription Drug User Fee Act (PDUFA) date of September 25, 2024 for the supplemental
BLA. KEYNOTE-483 is also under review in the EU and Japan.
Keytruda is under review in the EU and Japan in combination with chemotherapy (carboplatin and paclitaxel),
followed by Keytruda as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma,
based on the KEYNOTE-868 trial.
In addition, Keytruda is under review in the EU and Japan in combination with Padcev (enfortumab vedotin-ejfv), an
ADC, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma, based on the KEYNOTE-A39
trial that was conducted in collaboration with Seagen (now Pfizer Inc.) and Astellas. In July 2024, the EMA’s CHMP adopted a
positive opinion recommending approval of Keytruda in combination with Padcev for the first-line treatment of adult patients with
unresectable or metastatic urothelial carcinoma. The CHMP’s recommendation will now be reviewed by the EC for marketing
authorization in the EU, and a final decision is expected in the third quarter of 2024.
Keytruda is also under review in the EU and Japan in combination with chemoradiotherapy for the treatment of
patients with high-risk locally advanced cervical cancer, based on the KEYNOTE-A18 trial.
Keytruda is under review in Japan as part of a perioperative treatment regimen for certain patients with resectable
stage II, IIIA or IIIB (T3-4N2) NSCLC based on the KEYNOTE-671 study. A perioperative treatment regimen includes treatment
before surgery (neoadjuvant) and continued after surgery (adjuvant).
Welireg is under review in the EU for the treatment of VHL disease based on the LITESPARK-004 clinical trial and
and for the treatment of previously treated advanced RCC based on the LITESPARK-005 clinical trial. LITESPARK-005 is also
under review in Japan.
In May 2024, the Company announced that the Phase 3 KEYNOTE-B21 trial evaluating Keytruda in combination with
chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival for
the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent. At a pre-specified
interim analysis conducted by an independent Data Monitoring Committee (DMC), adjuvant treatment with Keytruda plus
- 41 -

-- 41 of 51 --

chemotherapy, with or without radiotherapy, did not meet the study’s pre-specified statistical criteria for disease-free survival
compared to placebo plus adjuvant chemotherapy, with or without radiotherapy. The study’s other primary endpoint of overall
survival was not formally tested since superiority was not reached for disease-free survival. A full evaluation of the data from this
study is ongoing. The Company will work with investigators to share the results with the scientific community.
Also In May 2024, the Company announced the discontinuation of the vibostolimab and pembrolizumab coformulation
arm of the Phase 3 KeyVibe-010 trial that is evaluating the regimen as adjuvant treatment for patients with resected high-risk
melanoma (Stage IIB-IV). At a pre-planned analysis, data showed that the primary endpoint of recurrence-free survival met the
pre-specified futility criteria. A higher rate of discontinuation of all adjuvant therapy by patients in the coformulation arm versus
the Keytruda-only arm, primarily due to immune-mediated adverse experiences, rendered it highly unlikely that the trial could
achieve a statistically significant improvement in recurrence-free survival. Based on the recommendation of an independent
DMC, the Company is unblinding the study and recommends that patients receiving the vibostolimab and pembrolizumab
coformulation be offered the option to be treated with Keytruda monotherapy. Data analysis from this study is ongoing. Results
will be shared with the scientific community and communicated to regulatory agencies.
The chart below reflects the Company’s research pipeline as of August 2, 2024. Candidates shown in Phase 3
include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced
compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for
commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine
candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the
same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line
products are not shown.
Phase 2
Cancer
MK-1022 (patritumab deruxtecan)(1)
Gastric
Head and Neck
Melanoma
MK-1308 (quavonlimab)(2)
Non-Small-Cell Lung
MK-1308A (quavonlimab+pembrolizumab)
Colorectal
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan)(1)
Bladder
Colorectal
Endometrial
Head and Neck
MK-2870 (sacituzumab tirumotecan)(1)(3)
Biliary
Colorectal
Neoplasm Malignant
Pancreatic
MK-3475 Keytruda
Advanced Solid Tumors
Prostate
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Cutaneous Squamous Cell
MK-4280 (favezelimab)(2)
Non-Small-Cell Lung
MK-4280A (favezelimab+pembrolizumab)
Bladder
Cutaneous Squamous Cell
Endometrial
Esophageal
Melanoma
Renal Cell
MK-5890 (boserolimab)(2)
Neoplasm Malignant
Cancer
MK-5909 (raludotatug deruxtecan)(1)
Ovarian
MK-6482 Welireg(3)
Endometrial
Esophageal
Hepatocellular
Prostate
Rare cancers
MK-7339 Lynparza(1)(3)
Advanced Solid Tumors
MK-7684A (vibostolimab+pembrolizumab)
Bladder
Colorectal
Endometrial
Melanoma
Ovarian
Prostate
Renal Cell
MK-7902 Lenvima(1)(2)
Head and Neck
V940(1)(2)
Cutaneous Squamous Cell
Bladder
Renal Cell
Dengue Fever Virus Vaccine
V181
Diabetic Macular Edema
MK-3000 Restoret
HIV-1 Infection
MK-8591B (islatravir+MK-8507)(4)
MK-8591D (islatravir+lenacapavir)(1)(5)
HIV-1 Prevention
MK-8527
Nonalcoholic Steatohepatitis (NASH)
MK-6024 (efinopegdutide)
Pulmonary Hypertension-Chronic
Obstructive Pulmonary Disease
MK-5475
Pulmonary Hypertension Due To Left Heart
Disease
MK-7962 Winrevair
Schizophrenia
MK-8189(6)
Thrombosis
MK-2060
Vitiligo
MK-6194
- 42 -

-- 42 of 51 --

Phase 3 (Phase 3 entry date) Under Review
Antiviral COVID-19
MK-4482 Lagevrio (U.S.) (May 2021)(1)(7)
Cancer
MK-1022 (patritumab deruxtecan)(1)
Non-Small-Cell Lung (May 2022) (EU)
MK-1026 (nemtabrutinib)
Hematological Malignancies (March 2023)
MK-1084
Non-Small-Cell Lung (May 2024)
MK-1308A (quavonlimab+pembrolizumab)
Renal Cell (April 2021)
MK-2400 (ifinatamab deruxtecan)(1)
Small-Cell Lung (July 2024)
MK-2870 (sacituzumab tirumotecan)(1)(3)
Breast (April 2024)
Cervical (July 2024)
Gastric (May 2024)
Endometrial (December 2023)
Non-Small-Cell Lung (November 2023)
MK-3475 Keytruda
Cutaneous Squamous Cell (August 2019) (EU)
Hepatocellular (May 2016) (EU)
Ovarian (December 2018)
Small-Cell Lung (May 2017)
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Non-Small-Cell Lung (February 2023)
MK-3543 (bomedemstat)
Myeloproliferative Disorders (December 2023)
MK-4280A (favezelimab+pembrolizumab)
Colorectal (November 2021)
Hematological Malignancies (October 2022)
MK-5684 (opevesostat)(1)
Prostate (December 2023)
MK-7339 Lynparza(1)(2)
Non-Small-Cell Lung (June 2019)
Small-Cell Lung (December 2020)
MK-7684A (vibostolimab+pembrolizumab)
Non-Small-Cell Lung (April 2021)
Small-Cell Lung (March 2022)
MK-7902 Lenvima(1)(2)
Esophageal (July 2021)
Gastric (December 2020)
V940(1)(2)
Melanoma (July 2023)
Non-Small-Cell Lung (December 2023)
HIV-1 Infection
MK-8591A (doravirine+islatravir) (February 2020)(5)
Hypercholesterolemia
MK-0616 (August 2023)
Respiratory Syncytial Virus
MK-1654 (clesrovimab) (November 2021)
Ulcerative Colitis
MK-7240 (tulisokibart) (October 2023)
New Molecular Entities
Cancer
MK-1022 (patritumab deruxtecan)(1)(8)
Non-Small-Cell Lung (U.S.)
MK-6482 Welireg
Von Hippel-Lindau (VHL) Disease (EU)
Cough
MK-7264 (gefapixant) (U.S.)(9)
Pneumococcal Vaccine Adult
V116 Capvaxive (EU)
Pulmonary Arterial Hypertension
MK-7962 Winrevair (EU)
Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• First-Line Unresectable Advanced or
Metastatic Malignant Pleural
Mesothelioma
(KEYNOTE-483) (U.S.) (EU) (JPN)
• Primary Advanced or Recurrent
Endometrial Carcinoma
(KEYNOTE-868) (EU) (JPN)
• First-Line Locally Advanced or Metastatic
Urothelial Carcinoma
(KEYNOTE-A39) (EU) (JPN)
• High-Risk Locally Advanced Cervical
Cancer
(KEYNOTE-A18) (EU) (JPN)
• Resectable Stage II, IIIA or IIIB (T3-4N2)
NSCLC
(KEYNOTE-671) (JPN)
MK-6482 Welireg
• Previously Treated Advanced Renal Cell
Carcinoma
(LITESPARK-005) (EU) (JPN)
Footnotes:
(1) Being developed in a collaboration.
(2) Being developed in combination with Keytruda.
(3) Being developed as monotherapy and/or in combination with Keytruda.
(4) On FDA clinical hold.
(5) On FDA partial clinical hold for higher doses than those used in current clinical trials.
(6) Phase 2b development costs are being co-funded.
(7) Available in the U.S. under Emergency Use Authorization.
(8) In June 2024, the FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working
with Daiichi Sankyo to address FDA feedback.
(9) In December 2023, the FDA issued a CRL for the NDA for gefapixant. Merck is reviewing the
FDA’s feedback to determine next steps.
Analysis of Liquidity and Capital Resources
($ in millions) June 30, 2024 December 31,
2023
Cash and investments $ 11,711 $ 7,345
Working capital 12,145 6,474
Total debt to total liabilities and equity 33.6 % 32.9 %
Cash provided by operating activities was $8.7 billion in the first six months of 2024 compared with $5.0 billion in the
first six months of 2023 reflecting stronger operating performance. Cash provided by operating activities was reduced by
milestone and option payments related to certain collaborations of $370 million and $240 million in the first six months of 2024
and 2023, respectively. Cash provided by operating activities continues to be the Company’s primary source of funds to finance
operating needs, with excess cash generally serving as the primary source of funds to finance business development
transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases.
Cash used in investing activities was $2.4 billion in the first six months of 2024 compared with $13.8 billion in the first
six months of 2023. The lower use of cash in investing activities was primarily due to lower cash used for acquisitions, lower
purchases of securities and other investments, as well as lower capital expenditures, partially offset by lower proceeds from
sales of securities and other investments.
Cash used in financing activities was $1.6 billion in the first six months of 2024 compared with cash provided by
financing activities of $1.7 billion in the first six months of 2023. The change was primarily due to lower proceeds from the
- 43 -

-- 43 of 51 --

issuance of debt, no proceeds from short-term borrowings and higher dividends paid to shareholders, partially offset by lower
payments on long-term debt, lower purchases of treasury stock and higher proceeds from the exercise of stock options.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell
accounts receivable. The Company factored $2.9 billion and $3.0 billion of accounts receivable at June 30, 2024 and
December 31, 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The
cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of
Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments
related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these
collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows.
In May 2024, MSD Netherlands Capital B.V., a wholly-owned finance subsidiary of Merck, completed a registered
public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of €850 million of 3.25%
senior notes due 2032, €850 million of 3.50% senior notes due 2037, €850 million of 3.70% senior notes due 2044 and
€850 million of 3.75% senior notes due 2054. The net cash proceeds from the offering were used for general corporate
purposes.
In March 2024, the Company’s $750 million, 2.90% notes matured in accordance with their terms and were repaid.
Dividends paid to stockholders were $3.9 billion and $3.7 billion for the first six months of 2024 and 2023,
respectively. In January 2024, Merck’s Board of Directors declared a quarterly dividend of $0.77 per share on the Company’s
outstanding common stock for the second quarter that was paid in April 2024. In May 2024, Merck’s Board of Directors declared
a quarterly dividend of $0.77 per share on the Company’s outstanding common stock for the third quarter of 2024 that was paid
in July 2024.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its
treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions,
block transactions on or off an exchange, or in privately negotiated transactions. During the first six months of 2024, the
Company purchased $373 million (3 million shares) of its common stock for its treasury under this program. As of June 30, 2024,
the Company’s remaining share repurchase authorization was $3.3 billion.
The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the
Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn
funding from this facility.
Critical Accounting Estimates
The Company’s significant accounting policies, which include management’s best estimates and judgments, are
included in Note 2 to the consolidated financial statements for the year ended December 31, 2023 included in Merck’s Form 10-K
filed on February 26, 2024. See Note 1 to the condensed consolidated financial statements for information on the adoption of a
new accounting standard during 2024. A discussion of accounting estimates considered critical because of the potential for a
significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical
Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations
included in Merck’s Form 10-K. There have been no significant changes in the Company’s critical accounting estimates since
December 31, 2023.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial
statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A.
Quantitative and Qualitative Disclosures about Market Risk” in the Company’s 2023 Form 10-K filed on February 26, 2024.
Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has
evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their
evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2024, the
Company’s disclosure controls and procedures are effective. For the second quarter of 2024, there were no changes in internal
control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control
over financial reporting.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-
called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and
uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-
looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and
- 44 -

-- 44 of 51 --

other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do
not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial
results, product approvals, product potential, development programs, environmental or other sustainability initiatives. One must
carefully consider any such statement and should understand that many factors could cause actual results to differ materially
from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks
and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and
actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully
evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and
Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on
Form 10-K for the year ended December 31, 2023, filed on February 26, 2024, the Company discusses in more detail various
important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors
for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to
predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all
potential risks or uncertainties.
PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 8 included in Part I, Item 1,
Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended June 30, 2024 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period
Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share
Total Number of Shares
Purchased as Part of Publicly
Announced Plans or
Programs
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
April 1 - April 30 408,640 $126.80 408,640 $3,527
May 1 - May 31 811,903 $129.33 811,903 $3,422
June 1 - June 30 727,448 $129.80 727,448 $3,328
Total 1,947,991 $128.97 1,947,991
(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s
common stock for its treasury.
Item 5. Other Information
Insider Trading Arrangements
During the three months ended June 30, 2024, none of the Company’s directors or executive officers adopted or
terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements.
- 45 -

-- 45 of 51 --

Item 6. Exhibits
Number Description
3.1 — Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) – Incorporated by reference
to Merck & Co., Inc.'s Current Report on Form 8-K filed on November 4, 2009 (No. 1-6571)
3.2 — By-Laws of Merck & Co., Inc. (effective March 22, 2022) – Incorporated by reference to Merck & Co., Inc.'s
Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)
31.1 — Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer
31.2 — Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer
32.1 — Section 1350 Certification of Chief Executive Officer
32.2 — Section 1350 Certification of Chief Financial Officer
101.INS — XBRL Instance Document - The instance document does not appear in the interactive data file because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH — XBRL Taxonomy Extension Schema Document.
101.CAL — XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF — XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB — XBRL Taxonomy Extension Label Linkbase Document.
101.PRE — XBRL Taxonomy Extension Presentation Linkbase Document.
104 — Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
- 46 -

-- 46 of 51 --

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
MERCK & CO., INC.
Date: August 5, 2024 /s/ Jennifer Zachary
JENNIFER ZACHARY
Executive Vice President and General Counsel
Date: August 5, 2024 /s/ Dalton Smart
DALTON SMART
Senior Vice President Finance - Global Controller
- 47 -

-- 47 of 51 --

Exhibit 31.1
CERTIFICATION
I, Robert M. Davis, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons
performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: August 5, 2024
By: /s/ Robert M. Davis
ROBERT M. DAVIS
Chairman, Chief Executive Officer and President

-- 48 of 51 --

Exhibit 31.2
CERTIFICATION
I, Caroline Litchfield, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons
performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: August 5, 2024
By: /s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

-- 49 of 51 --

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that
the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 5, 2024 /s/ Robert M. Davis
Name:
Title: ROBERT M. DAVIS
Chairman, Chief Executive Officer and President

-- 50 of 51 --

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that
the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 5, 2024 /s/ Caroline Litchfield
Name:
Title: CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

-- 51 of 51 --